<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="review-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">ANP</journal-id>
<journal-id journal-id-type="hwp">spanp</journal-id>
<journal-title>Australian &amp; New Zealand Journal of Psychiatry</journal-title>
<issn pub-type="ppub">0004-8674</issn>
<issn pub-type="epub">1440-1614</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage UK: London, England</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/0004867412449303</article-id>
<article-id pub-id-type="publisher-id">10.1177_0004867412449303</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Articles</subject>
<subj-group subj-group-type="heading">
<subject>Review</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>Mitochondrial modulators for bipolar disorder: A pathophysiologically informed paradigm for new drug development</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name><surname>Nierenberg</surname><given-names>Andrew A</given-names></name>
</contrib>
<contrib contrib-type="author">
<name><surname>Kansky</surname><given-names>Christine</given-names></name>
</contrib>
<contrib contrib-type="author">
<name><surname>Brennan</surname><given-names>Brian P</given-names></name>
</contrib>
<contrib contrib-type="author">
<name><surname>Shelton</surname><given-names>Richard C</given-names></name>
</contrib>
<contrib contrib-type="author">
<name><surname>Perlis</surname><given-names>Roy</given-names></name>
</contrib>
<contrib contrib-type="author">
<name><surname>Iosifescu</surname><given-names>Dan V</given-names></name>
</contrib>
<aff id="aff1-0004867412449303">Massachusetts General Hospital, Boston, MA, USA</aff>
</contrib-group>
<author-notes>
<corresp id="corresp1-0004867412449303">Andrew A Nierenberg, Massachusetts General Hospital, Suite 580, 50 Staniford Street, Boston, MA 02114, USA. Email: <email>anierenberg@partners.org</email></corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>1</month>
<year>2013</year>
</pub-date>
<volume>47</volume>
<issue>1</issue>
<issue-title>Special Issue DSM-5 Comes Alive</issue-title>
<fpage>26</fpage>
<lpage>42</lpage>
<permissions>
<copyright-statement>© The Royal Australian and New Zealand College of Psychiatrists 2012</copyright-statement>
<copyright-year>2012</copyright-year>
<copyright-holder content-type="society">The Royal Australian and New Zealand College of Psychiatrists</copyright-holder>
</permissions>
<abstract>
<sec id="section1-0004867412449303">
<title>Objectives:</title>
<p>Bipolar patients frequently relapse within 12 months of their previous mood episode, even in the context of adequate treatment, suggesting that better continuation and maintenance treatments are needed. Based on recent research of the pathophysiology of bipolar disorder, we review the evidence for mitochondrial dysregulation and selected mitochondrial modulators (MM) as potential treatments.</p>
</sec>
<sec id="section2-0004867412449303">
<title>Methods:</title>
<p>We reviewed the literature about mitochondrial dysfunction and potential MMs worthy of study that could improve the course of bipolar disorder, reduce subsyndromal symptoms, and prevent subsequent mood episodes.</p>
</sec>
<sec id="section3-0004867412449303">
<title>Results:</title>
<p>MM treatment targets mitochondrial dysfunction, oxidative stress, altered brain energy metabolism and the dysregulation of multiple mitochondrial genes in patients with bipolar disorder. Several tolerable and readily available candidates include <italic>N</italic>-acetyl-cysteine (NAC), acetyl-L-carnitine (ALCAR), <italic>S</italic>-adenosylmethionine (SAMe), coenzyme Q<sub>10</sub> (CoQ10), alpha-lipoic acid (ALA), creatine monohydrate (CM), and melatonin. The specific metabolic pathways by which these MMs may improve the symptoms of bipolar disorder are discussed and combinations of selected MMs could be of interest as well.</p>
</sec>
<sec id="section4-0004867412449303">
<title>Conclusions:</title>
<p>Convergent data implicate mitochondrial dysfunction as an important component of the pathophysiology of bipolar disorder. Clinical trials of individual MMs as well as combinations are warranted.</p>
</sec>
</abstract>
<kwd-group>
<kwd>Bipolar disorder</kwd>
<kwd>mitochondria</kwd>
<kwd>modulators</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="section5-0004867412449303" sec-type="intro">
<title>Introduction</title>
<p>Patients with bipolar disorder frequently experience multiple episodes of depression, mania, or hypomania, even if treated with the best available pharmacotherapy. Prospective longitudinal studies suggest that relapse rates within a year approach 67% for a cohort of bipolar patients with mostly inpatient index episodes (<xref ref-type="bibr" rid="bibr78-0004867412449303">Judd et al., 2008</xref>). The latest effectiveness trial information from the STEP-BD study showed about 50% of bipolar patients will relapse within 12 months of recovering from an outpatient index mood episode (<xref ref-type="bibr" rid="bibr132-0004867412449303">Perlis et al., 2006</xref>). Better continuation and maintenance treatments are needed.</p>
<p>We review potential mitochondrial modulators (MM) for the treatment of bipolar disorder that builds on recent findings on the pathophysiology of bipolar disorder. We focus on: (a) mitochondrial dysfunction in bipolar disorder (<xref ref-type="bibr" rid="bibr41-0004867412449303">Clay et al., 2011</xref>; <xref ref-type="bibr" rid="bibr88-0004867412449303">Konradi et al., 2004</xref>; <xref ref-type="bibr" rid="bibr118-0004867412449303">Munakata et al., 2004</xref>, <xref ref-type="bibr" rid="bibr117-0004867412449303">2007</xref>; <xref ref-type="bibr" rid="bibr121-0004867412449303">Naydenov et al., 2007</xref>; <xref ref-type="bibr" rid="bibr137-0004867412449303">Quiroz et al., 2008</xref>; <xref ref-type="bibr" rid="bibr160-0004867412449303">Shao et al., 2008b</xref>; <xref ref-type="bibr" rid="bibr174-0004867412449303">Stork and Renshaw, 2005</xref>; <xref ref-type="bibr" rid="bibr195-0004867412449303">Wang, 2007</xref>); (b) altered brain energy metabolism (<xref ref-type="bibr" rid="bibr56-0004867412449303">Frey et al., 2007a</xref>); and (c) an important convergent genetic finding about the alpha-1C subunit of the L-type calcium channel (<xref ref-type="bibr" rid="bibr168-0004867412449303">Sklar et al., 2008</xref>) along with calcium channel physiology associated with bipolar disorder, mitochondrial function and apoptosis. While each MM has the potential for treating bipolar disorder, it is possible that a combination of MMs (which target multiple points in the mitochondrial electron transport chain as well as oxidative stress) added to standard mood stabilizer treatment could reduce bipolar relapse or resurgence of mood symptoms. The purpose of this paper is to review the spectrum of MMs that could be considered for clinical trials. Of note, all MMs reviewed here are endogenous substances, currently available commercially as ‘nutraceuticals’ or dietary supplements.</p>
</sec>
<sec id="section6-0004867412449303">
<title>Background</title>
<p>Bipolar disorder, with a prevalence of about 1% for BPI and 1.1% for BPII, is associated with substantial lifelong disease burden and dysfunction and tends to be highly recurrent (<xref ref-type="bibr" rid="bibr113-0004867412449303">Merikangas et al., 2007</xref>; <xref ref-type="bibr" rid="bibr197-0004867412449303">Weissman et al., 1996</xref>). The NIMH Collaborative Depression Study followed a group of unipolar and bipolar patients for almost 25 years. Of the bipolar patients, most of who were recruited from inpatient settings, almost 67% experienced at least one relapse within a year of recovery, with a higher risk of relapse if they experienced residual mood symptoms (<xref ref-type="bibr" rid="bibr78-0004867412449303">Judd et al., 2008</xref>). A subset of bipolar participants in STEP-BD, who were followed prospectively after recovery from a mood episode, had recurrence rates of about 50% within 12 months, despite measurement-based, guideline-informed, systematic care with a fully available complement of modern psychopharmacological treatments – and these participants also had higher relapse rates if they had residual manic symptoms (<xref ref-type="bibr" rid="bibr132-0004867412449303">Perlis et al., 2006</xref>). Furthermore, subsyndromal symptoms of depression, mania and hypomania with associated dysfunction frequently persist between episodes (<xref ref-type="bibr" rid="bibr78-0004867412449303">Judd et al., 2008</xref>). Better treatments are needed to keep bipolar patients well, reduce subsyndromal symptoms, and prevent subsequent mood episodes.</p>
<p>Because the pathophysiology of bipolar disorder has yet to be determined, developing rational novel therapies presents a formidable challenge (<xref ref-type="bibr" rid="bibr110-0004867412449303">Mathew et al., 2008</xref>). Exciting new research that converges on mitochondrial dysfunction, however, could lead to a new drug development paradigm for the treatment of bipolar disorder (<xref ref-type="bibr" rid="bibr82-0004867412449303">Kato, 2008</xref>; <xref ref-type="bibr" rid="bibr86-0004867412449303">Kazuno et al., 2008</xref>; <xref ref-type="bibr" rid="bibr118-0004867412449303">Munakata et al., 2004</xref>, <xref ref-type="bibr" rid="bibr117-0004867412449303">2007</xref>). We postulate that MMs are candidates for novel treatments based on the latest studies of mitochondrial abnormalities (<xref ref-type="bibr" rid="bibr41-0004867412449303">Clay et al., 2011</xref>) and alterations of brain energy metabolism (<xref ref-type="bibr" rid="bibr56-0004867412449303">Frey et al., 2007a</xref>; <xref ref-type="bibr" rid="bibr174-0004867412449303">Stork and Renshaw, 2005</xref>) in bipolar disorder, as well as an important whole genome-wide association study that shows altered single nucleotide polymorphism (SNP) for L-type calcium channels (<xref ref-type="bibr" rid="bibr168-0004867412449303">Sklar et al., 2008</xref>). The strength of the approach is that it can address a range of dysfunctional mitochondrial targets, especially if combinations of MMs are used. It is possible that the effects of several MMs could be synergistic or target different abnormalities across the electron transport chain within mitochondria; alternatively, using several modulators may not be any better than using one. The potential use of multiple MMs is also consistent with the need for rational polypharmacy in bipolar patients and the finding that participants in STEP-BD took a median of three medications (<xref ref-type="bibr" rid="bibr62-0004867412449303">Ghaemi et al., 2006</xref>).</p>
</sec>
<sec id="section7-0004867412449303">
<title>Mitochondrial dysfunction in bipolar disorder</title>
<p>Multiple lines of evidence converge to strongly implicate mitochondrial dysfunction and oxidative stress in bipolar disorder (<xref ref-type="bibr" rid="bibr41-0004867412449303">Clay et al., 2011</xref>). While the degree of mitochondrial dysfunction may not be severe enough to manifest a systemic disorder, it may be enough to cause neuropsychiatric symptoms as the brain requires significantly more energy than any other organ in the body (<xref ref-type="bibr" rid="bibr133-0004867412449303">Peters et al., 2004</xref>). Mitochondria regulate energy production and generation of adenosine-5′-triphosphate (ATP) through the mitochondrial electron transport chain (ETC), with associated production of reactive oxygen species (ROS) that can result in oxidative stress and cellular damage, especially in the absence of sufficient antioxidant defenses (<xref ref-type="bibr" rid="bibr123-0004867412449303">Ng et al., 2008</xref>). In addition to oxidative processes, mitochondria regulate calcium and apoptotic processes, and are central to facilitating neuronal plasticity. Dysfunctional mitochondria can result in neuronal damage via multiple mechanisms: decreased ATP production, oxidative damage of membranes and DNA, abnormal calcium sequestration, and apoptosis via activation of caspase proteases (<xref ref-type="bibr" rid="bibr123-0004867412449303">Ng et al., 2008</xref>; <xref ref-type="bibr" rid="bibr195-0004867412449303">Wang, 2007</xref>). As reviewed below, mitochondrial dysfunction in bipolar disorder is associated with decreased ATP production, indicated by decreased brain energy metabolism and a shift from oxidative phosphorylation to anaerobic glycolysis (<xref ref-type="bibr" rid="bibr42-0004867412449303">Cui et al., 2007</xref>; <xref ref-type="bibr" rid="bibr56-0004867412449303">Frey et al., 2007a</xref>; <xref ref-type="bibr" rid="bibr121-0004867412449303">Naydenov et al., 2007</xref>; <xref ref-type="bibr" rid="bibr174-0004867412449303">Stork and Renshaw, 2005</xref>) (as shown by decreased phosphocreatine (PCr) and ATP in magnetic resonance spectroscopy (MRS) studies), upregulation of genes involved in apoptosis compared to patients with schizophrenia (<xref ref-type="bibr" rid="bibr23-0004867412449303">Benes et al., 2006</xref>), downregulation of mitochondrial genes regulating OXPHOS and proteasome degradation in bipolar disorder as compared to those with schizophrenia and healthy controls (<xref ref-type="bibr" rid="bibr88-0004867412449303">Konradi et al., 2004</xref>), decreased antioxidant defenses, including decreased superoxide dismutase and glutathione-peroxidase-1 and -4 (<xref ref-type="bibr" rid="bibr88-0004867412449303">Konradi et al., 2004</xref>), and increased lipid peroxidation, as well as abnormal calcium metabolism (<xref ref-type="bibr" rid="bibr82-0004867412449303">Kato, 2008</xref>; <xref ref-type="bibr" rid="bibr118-0004867412449303">Munakata et al., 2004</xref>). Moreover, abnormalities in the structure and distribution of mitochondria have been identified in brain and peripheral cells obtained from patients with bipolar disorder (<xref ref-type="bibr" rid="bibr37-0004867412449303">Cataldo et al., 2010</xref>). In summary, substantial evidence supports the hypothesis that mitochondrial dysfunction may play a central role in the pathophysiology of bipolar disorder.</p>
</sec>
<sec id="section8-0004867412449303">
<title>Oxidative phosphorylation and glycolysis</title>
<p>A study by <xref ref-type="bibr" rid="bibr121-0004867412449303">Naydenov et al. (2007)</xref>, in which they obtained lymphocytes from bipolar patients and healthy controls and examined differences in the pattern of expression of ETC genes in response to energy stress, provides insight into the possible nature of mitochondria dysregulation in bipolar disorder. This study showed no difference between bipolar patients and healthy controls in the expression of ETC genes under normal glucose concentrations. When cultured lymphocytes were exposed to glucose deprivation, however, bipolar patients displayed reduced expression of ETC genes while healthy controls uniformly increased ETC gene expression. This pattern suggests an inability of mitochondria in bipolar patients to adapt to energy stress.</p>
<p>The impaired response to energy stress observed in bipolar disorder described above is associated with several measurable effects of mitochondrial dysfunction including lower intracellular pH levels, increased lactate levels, and a decrease in overall energy production (<xref ref-type="bibr" rid="bibr45-0004867412449303">Dager et al., 2004</xref>; <xref ref-type="bibr" rid="bibr174-0004867412449303">Stork and Renshaw, 2005</xref>). Studies utilizing MRS showed that compared to normal controls, bipolar patients not taking medication had increased cerebral lactate levels, specifically in the gray matter (<xref ref-type="bibr" rid="bibr45-0004867412449303">Dager et al., 2004</xref>). Moreover, lower pH levels have been reported in the basal ganglia region and whole brain of euthymic bipolar subjects in comparison to individuals without bipolar disorder (<xref ref-type="bibr" rid="bibr71-0004867412449303">Hamakawa et al., 2004</xref>).</p>
<p>Under energy stress, mitochondria usually rely on glycolysis for a quick source of ATP energy. During this anaerobic cellular respiration process, nicotine adenine dinucleotide (NADH) is converted to NAD, thereby reducing pyruvate to lactate and causing a subsequent decrease in intracellular pH levels. While glycolysis is a readily available source of energy, it only manufactures 2 ATP per glucose molecule in contrast to the 36 ATP produced through oxidation phosphorylation (<xref ref-type="bibr" rid="bibr123-0004867412449303">Ng et al., 2008</xref>). In bipolar disorder, MRS studies have documented increased lactate (<xref ref-type="bibr" rid="bibr45-0004867412449303">Dager et al., 2004</xref>; <xref ref-type="bibr" rid="bibr83-0004867412449303">Kato et al., 1998</xref>) and lowered pH levels (<xref ref-type="bibr" rid="bibr71-0004867412449303">Hamakawa et al., 2004</xref>; <xref ref-type="bibr" rid="bibr83-0004867412449303">Kato et al., 1998</xref>) suggesting that neurons are constantly relying on the largely inefficient process of glycolysis to produce energy. Overall, these findings provide evidence that, compared to normal controls, the total energy output of mitochondria in bipolar disorder is inhibited.</p>
</sec>
<sec id="section9-0004867412449303">
<title>Brain energy metabolism in bipolar disorder</title>
<p>Multiple reports using MRS have also suggested that bipolar disorder is characterized by abnormalities of brain energy metabolism, consistent with mitochondrial dysfunction. Proton MRS (<sup>1</sup>H-MRS) studies show decreased cerebral <italic>N</italic>-acetyl-aspartate (NAA) in bipolar subjects compared to normal controls (<xref ref-type="bibr" rid="bibr29-0004867412449303">Bertolino et al., 2003</xref>; <xref ref-type="bibr" rid="bibr48-0004867412449303">Deicken et al., 2003</xref>). Decreased levels of NAA, a marker of neuronal viability, are consistent with impaired mitochondrial energy production (<xref ref-type="bibr" rid="bibr40-0004867412449303">Clark, 1998</xref>) as NAA is of mitochondrial origin: NAA is synthesized in mitochondria by the membrane-bound enzyme L-aspartate <italic>N</italic>-acetyltransferase, a catalyst that is found only in the brain (<xref ref-type="bibr" rid="bibr131-0004867412449303">Patel and Clark, 1979</xref>).</p>
<p>Phosphorus MRS (<sup>31</sup>P-MRS) studies allow measurements of high-energy compounds such as ATP and PCr – a reservoir for the generation of ATP that has been found to be altered in bipolar patients (<xref ref-type="bibr" rid="bibr85-0004867412449303">Kato et al., 1994</xref>, <xref ref-type="bibr" rid="bibr84-0004867412449303">1995</xref>). During periods of acute neuronal activity, as ATP is utilized and depleted, PCr is rapidly broken down in order to maintain the overall concentration of ATP (<xref ref-type="bibr" rid="bibr51-0004867412449303">Erecinska and Silver, 1989</xref>). Long-term abnormalities in PCr levels generally reflect much larger alterations in cellular metabolism and, in particular, an insufficient supply of the ATP needed for normal cellular function (<xref ref-type="bibr" rid="bibr150-0004867412449303">Rothman, 1994</xref>). Therefore, continually decreased levels of PCr are suggestive of hypometabolism, possibly due to mitochondrial dysfunction (<xref ref-type="bibr" rid="bibr114-0004867412449303">Modica-Napolitano and Renshaw, 2004</xref>). Persistently low brain PCr values have also been found in patients with a variety of mitochondrial disorders (e.g. mitochondrial encephalomyopathy, lactic acidosis and stroke-like episodes (MELAS), Leigh’s disease, progressive external ophthalmoplegia (PEO), and Leber’s hereditary optic neuropathy) (<xref ref-type="bibr" rid="bibr20-0004867412449303">Barbiroli et al., 1993</xref>; <xref ref-type="bibr" rid="bibr49-0004867412449303">Eleff et al., 1990</xref>).</p>
<p>Indirectly, abnormalities of lipid metabolism, an energy-intensive process (<xref ref-type="bibr" rid="bibr136-0004867412449303">Purdon and Rapoport, 1998</xref>), are also supportive of the mitochondrial dysfunction and associated bioenergetic deficits in bipolar disorder. Multiple studies have suggested that total choline levels are elevated in bipolar disorder (<xref ref-type="bibr" rid="bibr70-0004867412449303">Hamakawa et al., 1998</xref>; <xref ref-type="bibr" rid="bibr91-0004867412449303">Lafer et al., 1994</xref>; <xref ref-type="bibr" rid="bibr115-0004867412449303">Moore et al., 2000</xref>). Phosphomonoester (PME) levels (which primarily include the lipid membrane precursors phosphocholine and phosphoethanolamine) are also altered in bipolar disorder. Euthymic bipolar patients show decreased PME levels compared with healthy volunteers (<xref ref-type="bibr" rid="bibr201-0004867412449303">Yildiz et al., 2001</xref>). Both series of findings suggest impaired lipid membrane metabolism in bipolar disorder. This is important, as lipid membrane turnover represents 10–15% of total energetic requirements in the cell (<xref ref-type="bibr" rid="bibr136-0004867412449303">Purdon and Rapoport, 1998</xref>).</p>
</sec>
<sec id="section10-0004867412449303">
<title>Mitochondrial gene expression in bipolar disorder</title>
<p>Multiple mitochondrial genes have been found to be upregulated or downregulated in bipolar disorder compared to normal controls (<xref ref-type="bibr" rid="bibr23-0004867412449303">Benes et al., 2006</xref>; <xref ref-type="bibr" rid="bibr118-0004867412449303">Munakata et al., 2004</xref>; <xref ref-type="bibr" rid="bibr121-0004867412449303">Naydenov et al., 2007</xref>; <xref ref-type="bibr" rid="bibr177-0004867412449303">Sun et al., 2006</xref>; <xref ref-type="bibr" rid="bibr195-0004867412449303">Wang, 2007</xref>). Mitochondrial DNA (mtDNA) contains 37 genes, 13 encoding for subunits of the respiratory chain complexes I, III, IV and V, 22 encoding for transfer RNAs, and two for ribosomal RNAs (<xref ref-type="bibr" rid="bibr185-0004867412449303">Taylor and Turnbull, 2005</xref>). MtDNA differs somewhat from autosomal (nuclear) DNA: it is not protected by any repair mechanism or histones, does not undergo any recombination during meiosis, and is maternally inherited. Notably, polymorphisms are estimated to occur up to 10 times more frequently than in autosomal DNA, probably owing to closeness to free radical production and absence of an effective DNA repair mechanism (<xref ref-type="bibr" rid="bibr185-0004867412449303">Taylor and Turnbull, 2005</xref>).</p>
<p>Because of the compact nature of mtDNA, it has been demonstrated that genotyping a small number of single-nucleotide polymorphisms can capture nearly all common variation in the mitochondrial genome. Specifically, Saxena and colleagues reported a set of SNPs that efficiently ‘tag’ common mitochondrial variation (<xref ref-type="bibr" rid="bibr158-0004867412449303">Saxena et al., 2006</xref>). In light of the evidence presented above, such variations would have a high prior probability of association with differential treatment response.</p>
<p>Mitochondrial variation is also of particular interest in light of the recent association between calcium channel variation and bipolar disorder (<xref ref-type="bibr" rid="bibr55-0004867412449303">Ferreira et al., 2008</xref>; <xref ref-type="bibr" rid="bibr168-0004867412449303">Sklar et al., 2008</xref>). Specifically, mitochondria and endoplasmic reticulum (ER) function in concert to sequester Ca<sup>2+</sup> ions after their temporary diffusion in subcellular regions. A massive movement of positively charged Ca<sup>2+</sup> into the mitochondrion could exceed its capacity to export cations, impairing ATP synthesis and promoting apoptosis (<xref ref-type="bibr" rid="bibr27-0004867412449303">Bernardi et al., 1998</xref>). Of note, animal, in vitro and mRNA studies demonstrate that chronic lithium treatment, as well as therapeutic doses of valproic acid and electroconvulsive stimulus, increase the expression of Bcl-2 (<xref ref-type="bibr" rid="bibr38-0004867412449303">Chang et al., 2009</xref>; <xref ref-type="bibr" rid="bibr39-0004867412449303">Chen et al., 1999</xref>). In turn, one of the main effects of the anti-apoptotic protein Bcl-2 is increasing the stability of the mitochondrial permeability transition pore (MPTP) (<xref ref-type="bibr" rid="bibr196-0004867412449303">Weeber et al., 2002</xref>).</p>
</sec>
<sec id="section11-0004867412449303">
<title>Bcl-2, BDNF, neuroprotection and mitochondria as pathophysiology and targets of treatments</title>
<p>Mitochondria play important roles in the regulation of intracellular calcium (Ca<sup>2+</sup>), and in the general process of synaptic plasticity (<xref ref-type="bibr" rid="bibr200-0004867412449303">Yang et al., 2003</xref>). Excessive opening of N-methyl-d-aspartate (NMDA) glutamate receptors can trigger large influxes of Ca<sup>2+</sup>, which in turn can overwhelm the ability of mitochondria to export protons and cations (<xref ref-type="bibr" rid="bibr124-0004867412449303">Nicholls and Ward, 2000</xref>) and can lead to drastic reduction in ATP synthesis (<xref ref-type="bibr" rid="bibr196-0004867412449303">Weeber et al., 2002</xref>); at the extreme, this can lead to initiation of apoptosis (<xref ref-type="bibr" rid="bibr27-0004867412449303">Bernardi et al., 1998</xref>). Activation of mitochondrial apoptotic mechanisms may lead to selective destruction of synapses (<xref ref-type="bibr" rid="bibr44-0004867412449303">Culmsee and Mattson, 2005</xref>). This may be related to neuroplasticity and synaptic pruning in normal conditions, but is also involved with extensive loss of synapses in pathological conditions associated with mitochondrial dysfunction (<xref ref-type="bibr" rid="bibr111-0004867412449303">Mattson and Liu, 2003</xref>).</p>
<p>In bipolar disorder, patients with the val66met polymorphism of the BDNF gene (which may be associated with rapid cycling (<xref ref-type="bibr" rid="bibr116-0004867412449303">Müller et al., 2006</xref>)) also have low levels of PCr + Cr in the dorsolateral prefrontal cortex (suggestive of low bioenergetic metabolism (<xref ref-type="bibr" rid="bibr57-0004867412449303">Frey et al., 2007b</xref>)). Rats treated with therapeutic doses of lithium and valproic acid have increased levels of Bcl-2 (<xref ref-type="bibr" rid="bibr108-0004867412449303">Manji et al., 2000</xref>). Bcl-2 and other neuroprotective agents from its family (Bcl-xl) exert their anti-apoptotic and neuroprotective activity by increasing the ability of mitochondria to resist the toxic effect of elevated intracellular Ca<sup>2+</sup> (<xref ref-type="bibr" rid="bibr119-0004867412449303">Murphy et al., 1996</xref>).</p>
<p>The presence of mitochondrial dysfunction in bipolar disorder and the link between current effective treatments in bipolar disorder (lithium, valproic acid), major neuroprotective factors (Bcl-2, BDNF and GSK-3) and their impact on mitochondrial activity may justify enhancing mitochondrial function as a putative target in the search of future mood stabilizers.</p>
</sec>
<sec id="section12-0004867412449303">
<title>Candidate mitochondrial modulators</title>
<p>Several readily available dietary supplements (or nutraceuticals) have been tested as potential treatments in bipolar disorder (for a review see <xref ref-type="bibr" rid="bibr156-0004867412449303">Sarris et al., 2011</xref>). Among them, a subset of substances has the potential to improve mitochondrial function and brain energy metabolism; those are grouped here under the term ‘mitochondrial modulators’. Candidates include <italic>N</italic>-acetyl-cysteine (NAC), acetyl-L-carnitine (ALCAR), <italic>S</italic>-adenosylmethionine (SAMe), coenzyme Q<sub>10</sub> (CoQ10), alpha-lipoic acid (ALA), creatine monohydrate (CM), and melatonin. As pointed out by Hagen and colleagues, increased mitochondrial metabolism can result in decreased antioxidant status – and the decreased antioxidant status may need to be offset by providing an additional antioxidant such as ALA (<xref ref-type="bibr" rid="bibr65-0004867412449303">Hagen et al., 2002a</xref>) – alternatively, NAC may provide the sufficient antioxidant properties (by increasing glutathione) without ALA. Furthermore, allostatic load in bipolar disorder has been reported to be increased, as evidenced by high levels of ROS (<xref ref-type="bibr" rid="bibr80-0004867412449303">Kapczinski et al., 2008</xref>) and MMs could prevent ROS damage.</p>
<sec id="section13-0004867412449303">
<title>N-acetyl-cysteine (NAC)</title>
<p>NAC, by supplying cysteine, increases synthesis of the free radical scavenger glutathione (GSH) which, in turn, reduces oxidative stress (<xref ref-type="bibr" rid="bibr18-0004867412449303">Atkuri et al., 2007</xref>). Glutathione (GSH), a tripeptide composed of glutamate, cysteine and glycine, is the most abundant thiol antioxidant. Glutamate-cysteine ligase (GCL) is the rate-limiting enzyme for GSH production – GCL ligates glutamate with cysteine to form gamma-glutamyl-cysteine which is then combined with glycine and catalyzed by GSH synthase to form GSH (<xref ref-type="bibr" rid="bibr42-0004867412449303">Cui et al., 2007</xref>). As an antioxidant, GSH reacts with hydrogen peroxide H<sub>2</sub>O<sub>2</sub> to form H<sub>2</sub>O with the byproduct of GSH disulfide. Also, GSH can conjugate with oxidized products, catalyzed by glutathione-<italic>S</italic>-transferase (GST) to further reduce oxidative stress.</p>
<p>Lithium and valproate have well-known neuroprotective effects that may be mediated by increasing GSH and GCL levels. In cultured rat cerebral cortical cell cultures, the neuroprotective effects of lithium and valproate against oxidative damage from H<sub>2</sub>O<sub>2</sub> is abolished by depletion of GSH (<xref ref-type="bibr" rid="bibr42-0004867412449303">Cui et al., 2007</xref>). Furthermore, one mechanism of neuroprotection of lithium may be through GSH, since lithium increases the gene expression of GST isoenzymes (<xref ref-type="bibr" rid="bibr159-0004867412449303">Shao et al., 2008a</xref>). NAC can increase GSH further (and potentially synergistically with lithium or valproate) by driving synthesis of glutathione to the right with increased cysteine availability.</p>
<p>Oral NAC prevents glutathione depletion in the brain by increasing cysteine and synthesis of glutathione systemically (<xref ref-type="bibr" rid="bibr24-0004867412449303">Berk et al., 2008a</xref>/<xref ref-type="bibr" rid="bibr25-0004867412449303">b</xref>). Furthermore, NAC has been found to be neuroprotective and can prevent oxidative damage in complex 1 in the mitochondrial electron transport chain (<xref ref-type="bibr" rid="bibr112-0004867412449303">Mayer and Noble, 1994</xref>; <xref ref-type="bibr" rid="bibr125-0004867412449303">Nicoletti et al., 2005</xref>). Clinically, NAC augmentation reduced negative symptoms and improved auditory processing in schizophrenia (<xref ref-type="bibr" rid="bibr24-0004867412449303">Berk et al., 2008a</xref>/<xref ref-type="bibr" rid="bibr25-0004867412449303">b</xref>), improved pathological gambling in a pilot study (<xref ref-type="bibr" rid="bibr63-0004867412449303">Grant et al., 2007</xref>), and is a prime candidate to improve mitochondrial function, and perhaps the long-term course, in bipolar disorder.</p>
<p>In a preliminary, double-blind study of bipolar patients (<italic>n</italic> = 75) who had experienced a mood episode in the past 6 months and who had been stable for at least 1 month, NAC 2 grams per day or placebo was added to ongoing medications (<xref ref-type="bibr" rid="bibr24-0004867412449303">Berk et al., 2008a</xref>/<xref ref-type="bibr" rid="bibr25-0004867412449303">b</xref>). At baseline, half the patients were euthymic, about a third were depressed, and about 15% had euphoric or dysphoric mania. Measures of depression, quality of life, and functioning were all better with NAC compared to placebo beginning at week 12 and continuing until week 24; no differences were found in manic or hypomanic symptoms, but these symptoms were minimal at baseline and during the study. The delayed effect of NAC (observed first at week 12) may be a result of the study design, as most patients were euthymic at baseline. Improvements in mood that occurred during the trial stopped after discontinuation of NAC.</p>
</sec>
<sec id="section14-0004867412449303">
<title>Acetyl-L-carnitine (ALCAR)</title>
<p>L-Carnitine, composed of lysine and methionine, can be endogenously generated or obtained through diet (<xref ref-type="bibr" rid="bibr76-0004867412449303">Hoppel, 2003</xref>). Carnitines transport fatty acids into mitochondria for beta-oxidation and energy generation, and scavenge ROS (<xref ref-type="bibr" rid="bibr7-0004867412449303">Al-Majed et al., 2006</xref>; <xref ref-type="bibr" rid="bibr138-0004867412449303">Rebouche, 2004</xref>). These fatty acids enter mitochondria as acyl-carnitines, and when oxidized, release energy and form acyl-coenzyme A, which then enters the citric acid cycle (<xref ref-type="bibr" rid="bibr76-0004867412449303">Hoppel, 2003</xref>). ALCAR, absorbed better than L-carnitine and more able to cross the blood–brain barrier than L-carnitine (Ames and Liu, 2004a), has neuroprotective and anti-apoptotic properties (<xref ref-type="bibr" rid="bibr7-0004867412449303">Al-Majed et al., 2006</xref>; <xref ref-type="bibr" rid="bibr193-0004867412449303">Virmani et al., 2005</xref>) and has been shown to block glutamate-induced over-expression of glutamic acid decarboxylase GAD67 (<xref ref-type="bibr" rid="bibr72-0004867412449303">Hao et al., 2004</xref>), the main enzyme that converts glutamate to gamma-amino-butyric acid (GABA). ALCAR appears to reverse age-related degeneration in animal models (<xref ref-type="bibr" rid="bibr6-0004867412449303">Aliev et al., 2009</xref>; Ames and Liu, 2004a, 2004b; <xref ref-type="bibr" rid="bibr65-0004867412449303">Hagen et al., 2002a</xref>; <xref ref-type="bibr" rid="bibr102-0004867412449303">Liu et al., 2002b</xref>) and may slow down or reverse age-related cognitive and motoric decline in rats, as well as reverse diminished reactivity to the environment (<xref ref-type="bibr" rid="bibr65-0004867412449303">Hagen et al., 2002a</xref>) – effects thought to result from enhanced mitochondrial functioning. Notably, adult and aged rats administered ALCAR both show an increase in brain levels of ATP and PCr as measured by <sup>1</sup>H nuclear magnetic resonance spectroscopy (NMR) (<xref ref-type="bibr" rid="bibr19-0004867412449303">Aureli et al., 1990</xref>). However, evidence that ALCAR can decrease oxidative stress is mixed (Ames and Liu, 2004a), suggesting that it may be more clinically effective when administered with a potent antioxidant such as NAC or ALA (see below).</p>
<p>Clinically, ALCAR has shown benefit in clinical trials for a number of neuropsychiatric disorders including dementia (<xref ref-type="bibr" rid="bibr30-0004867412449303">Bonavita, 1986</xref>; <xref ref-type="bibr" rid="bibr130-0004867412449303">Passeri et al., 1990</xref>; <xref ref-type="bibr" rid="bibr134-0004867412449303">Pettegrew et al., 1995</xref>; <xref ref-type="bibr" rid="bibr153-0004867412449303">Salvioli and Neri, 1994</xref>; <xref ref-type="bibr" rid="bibr155-0004867412449303">Sano et al., 1992</xref>; <xref ref-type="bibr" rid="bibr172-0004867412449303">Spagnoli et al., 1991</xref>), geriatric depression (<xref ref-type="bibr" rid="bibr21-0004867412449303">Bella et al., 1990</xref>; <xref ref-type="bibr" rid="bibr58-0004867412449303">Fulgente et al., 1990</xref>; <xref ref-type="bibr" rid="bibr60-0004867412449303">Garzya et al., 1990</xref>; <xref ref-type="bibr" rid="bibr61-0004867412449303">Gecele et al., 1991</xref>; <xref ref-type="bibr" rid="bibr120-0004867412449303">Nasca et al., 1989</xref>; <xref ref-type="bibr" rid="bibr135-0004867412449303">Pettegrew et al., 2002</xref>; <xref ref-type="bibr" rid="bibr186-0004867412449303">Tempesta et al., 1987</xref>; <xref ref-type="bibr" rid="bibr191-0004867412449303">Villardita et al., 1983</xref>), dysthymia (<xref ref-type="bibr" rid="bibr203-0004867412449303">Zanardi and Smeraldi, 2006</xref>), hyperactivity associated with fragile X syndrome (<xref ref-type="bibr" rid="bibr188-0004867412449303">Torrioli et al., 1999</xref>, <xref ref-type="bibr" rid="bibr189-0004867412449303">2008</xref>), ADHD, inattentive type (<xref ref-type="bibr" rid="bibr17-0004867412449303">Arnold et al., 2007</xref>), degenerative cerebellar ataxia (<xref ref-type="bibr" rid="bibr171-0004867412449303">Sorbi et al., 2000</xref>), minimal hepatic encephalopathy (<xref ref-type="bibr" rid="bibr106-0004867412449303">Malaguarnera et al., 2008</xref>), and hepatic coma secondary to cirrhosis (<xref ref-type="bibr" rid="bibr107-0004867412449303">Malaguarnera et al., 2006</xref>), and has demonstrated benefit in disorders thought to be associated with deficits in neuronal mitochondrial energy production such as diabetic peripheral neuropathy (<xref ref-type="bibr" rid="bibr47-0004867412449303">De Grandis and Minardi, 2002</xref>; <xref ref-type="bibr" rid="bibr167-0004867412449303">Sima et al., 2005</xref>) and HIV-associated antiretroviral toxic neuropathy (<xref ref-type="bibr" rid="bibr73-0004867412449303">Hart et al., 2004</xref>; <xref ref-type="bibr" rid="bibr202-0004867412449303">Youle and Osio, 2007</xref>). One study investigating the weight-reducing effects of ALCAR in bipolar patients who had gained weight while taking valproate found no difference in weight between those taking ALCAR with diet compared to diet alone (<xref ref-type="bibr" rid="bibr50-0004867412449303">Elmslie et al., 2006</xref>). Interestingly, valproate-induced hepatotoxicity may be mediated by inhibition of mitochondrial fatty acid beta-oxidation and depletion of carnitine, suggesting that carnitine supplementation, perhaps through administration of ALCAR, may either prevent or reverse valproate-induced hepatotoxicity (<xref ref-type="bibr" rid="bibr166-0004867412449303">Silva et al., 2008</xref>).</p>
<p>Importantly, ALCAR has demonstrated efficacy in a variety of depressive spectrum disorders in several placebo-controlled studies (<xref ref-type="bibr" rid="bibr21-0004867412449303">Bella et al., 1990</xref>; <xref ref-type="bibr" rid="bibr58-0004867412449303">Fulgente et al., 1990</xref>; <xref ref-type="bibr" rid="bibr60-0004867412449303">Garzya et al., 1990</xref>; <xref ref-type="bibr" rid="bibr61-0004867412449303">Gecele et al., 1991</xref>; <xref ref-type="bibr" rid="bibr120-0004867412449303">Nasca et al., 1989</xref>; <xref ref-type="bibr" rid="bibr135-0004867412449303">Pettegrew et al., 2002</xref>; <xref ref-type="bibr" rid="bibr186-0004867412449303">Tempesta et al., 1987</xref>; <xref ref-type="bibr" rid="bibr191-0004867412449303">Villardita et al., 1983</xref>; <xref ref-type="bibr" rid="bibr203-0004867412449303">Zanardi and Smeraldi, 2006</xref>). In addition, a preliminary study in depressed geriatric patients demonstrated improvement in depression symptoms that were associated with an increase in PCr as measured by <sup>31</sup>P-MRS after monotherapy treatment with ALCAR (<xref ref-type="bibr" rid="bibr135-0004867412449303">Pettegrew et al., 2002</xref>). However, no clinical trials, to our knowledge, have yet examined the effect of ALCAR supplementation in individuals with bipolar disorder.</p>
</sec>
<sec id="section15-0004867412449303">
<title>S-Adenosylmethionine (SAMe)</title>
<p>SAMe, formed from methionine and ATP, is a naturally occurring biological component of all living cells, and plays a critical role in cellular metabolism as a major source of methyl groups for key biochemical reactions (<xref ref-type="bibr" rid="bibr31-0004867412449303">Bottiglieri, 1996</xref>; <xref ref-type="bibr" rid="bibr32-0004867412449303">Bottiglieri et al., 2000</xref>). Specifically as a methyl donor, SAMe is a precursor molecule for pathways catalyzed by methyltransferase enzymes, such as methylation, transulfuration and aminopropylation.</p>
<p>Methylation via SAMe is a particularly important process in the central nervous system. SAMe is integral in the degradation and repair of proteins with aberrant levels of <sc>d</sc>-aspartate that can accumulate during protein aging and lead to cellular abnormalities and dysfunction (<xref ref-type="bibr" rid="bibr31-0004867412449303">Bottiglieri, 1996</xref>; <xref ref-type="bibr" rid="bibr32-0004867412449303">Bottiglieri et al., 2000</xref>). SAMe-mediated methylation reactions also are important in the monoamine metabolism. As a methyl donor, SAMe activates tyrosine hydroxylase, an essential enzyme for the synthesis as well as the excitatory and inhibitory regulation of various monoamine neurotransmitters, including dopamine, serotonin, adrenaline and noradrenaline.</p>
<p>SAMe is also a precursor molecule for GSH production through transulfuration. <italic>S</italic>-Adenosyl-homocysteine (SAH), formed when SAMe donates its methyl group, is rapidly metabolized to homocysteine. Homocysteine, when paired with several B vitamin cofactors, including pyridoxal phosphate (vitamin B-6), is converted into cystathionine and eventually, through transulfuration, converted to GSH. As discussed earlier in the section on NAC, GSH plays an essential role in reducing oxidative stress. Homocysteine can also regenerate SAMe when a sufficient concentration of B vitamins triggers its remethylation.</p>
<p>Clinically, SAMe evidence supports the antidepressant effects for individuals with depressive disorders, with fewer side effects than standard medications such as imipramine, chlorimipramine, nomifensive and minaprine (<xref ref-type="bibr" rid="bibr31-0004867412449303">Bottiglieri, 1996</xref>; <xref ref-type="bibr" rid="bibr32-0004867412449303">Bottiglieri et al., 2000</xref>). The results of an open label trial of SAMe treatment in depressed inpatients supported the clinical value of SAMe supplementation such that patients experienced remission or improvement of their symptoms with minimal side effects after a 2-week period (<xref ref-type="bibr" rid="bibr99-0004867412449303">Lipinski et al., 1984</xref>). More recent research has investigated the efficacy and tolerability of SAMe when combined with other traditional antidepressant medication. When SAMe was added to selective serotonin reuptake inhibitors (SSRI) antidepressants or venlafaxine, individuals with unremitted depression showed significant improvements, including a decrease in both depression-severity and clinical global impressions severity scores as assessed by the HAM-D and CGI scales, respectively (<xref ref-type="bibr" rid="bibr8-0004867412449303">Alpert et al., 2004</xref>). In a recent randomized controlled trial, SAMe augmentation of antidepressants was more efficacious than placebo augmentation in unipolar depressed subjects not responding to a course of selective serotonin reuptake inhibitors (SSRIs) or serotonin norepinephrine reuptake inhibitors (SNRIs) (<xref ref-type="bibr" rid="bibr128-0004867412449303">Papakostas et al., 2010</xref>). While evidence for efficacy exists when SAMe is combined with imipramine (<xref ref-type="bibr" rid="bibr26-0004867412449303">Berlanga et al., 1992</xref>), the results for SAMe augmentation with older antidepressants, including phenelzine, mianserin and maprotiline (<xref ref-type="bibr" rid="bibr9-0004867412449303">Alvarez et al., 1987</xref>) showed inconsistent results. Of note, SAMe may also carry a risk of manic switch in bipolar disorder. In an earlier study, nine of 11 bipolar patients treated with SAMe switched into elevated mood state (hypomania, mania and euphoria) while the other two did not respond (<xref ref-type="bibr" rid="bibr36-0004867412449303">Carney et al., 1989</xref>). To the best of our knowledge, no systematic randomized controlled studies of SAMe for bipolar disorder have been conducted to date.</p>
</sec>
<sec id="section16-0004867412449303">
<title>Coenzyme Q<sub>10</sub> (CoQ10)</title>
<p>Coenzyme Q<sub>10</sub> (CoQ10) consists of polyisopropyl units (usually 9 or 10) attached to a benzoquinone ring that can alternate between free radical ubisemiquinone (*QH), and fully reduced ubiquinol (QH<sub>2</sub>) (<xref ref-type="bibr" rid="bibr90-0004867412449303">Kwong et al., 2002</xref>). The ability to assume multiple redox states allows for CoQ10 to play several functional roles in the cells, not all of which are well understood. CoQ10 acts as a lipid-soluble antioxidant that can prevent cell damage by neutralizing free radicals directly or by reducing an alpha-tocopheroxyl radical to alpha-tocopherol, an absorbable form of vitamin E. Another important function of CoQ10, present in high concentrations within the inner mitochondrial layer, is its ability to generate an electrochemical gradient along the transmembrane of mitochondria. The quinine head of CoQ transfers electrons in the mitochondrial electron transport chain from complexes I and II to complex III while releasing protons into the intermembrane.</p>
<p>While CoQ10 naturally decreases with aging in various tissues, abnormal levels of CoQ10 are also associated with conditions such as hypertension, diabetes, cardiovascular disease, and neurodegenerative disorders such as Parkinson’s disease.</p>
<p>Plasma and mitochondrial brain levels of CoQ10 in individuals with Parkinson’s disease were significantly lower than non-parkinsonian controls of the same gender and age (<xref ref-type="bibr" rid="bibr162-0004867412449303">Shults and Haas, 2005</xref>). While the total level of plasma CoQ10 was reduced in subjects with Parkinson’s disease, the percentage of oxidized plasma CoQ10 (ubiquinone-10) was increased (<xref ref-type="bibr" rid="bibr170-0004867412449303">Sohmiya et al., 2004</xref>). Because CoQH<sub>2</sub><sup>–</sup>10 (e.g. ubiquinol-10) is oxidized to CoQ10 with early plasma oxidation, high levels of CoQ10 may serve as a biomarker of oxidative stress in the mitochondria. A significant correlation was also found between the level of CoQ10 and the activity levels of complex I and II/III. Impaired activity of complex I, II and III was observed in platelet mitochondria of patients with early, untreated Parkinson’s disease (<xref ref-type="bibr" rid="bibr164-0004867412449303">Shults et al., 1997</xref>).</p>
<table-wrap id="table1-0004867412449303" position="float">
<label>Table 1.</label>
<caption>
<p>Evidence for mitochodrial dysfunction in bipolar (BP) disorder.</p>
</caption>
<graphic alternate-form-of="table1-0004867412449303" xlink:href="10.1177_0004867412449303-table1.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup>
<thead>
<tr>
<th/>
<th align="left">Bipolar disorder</th>
<th align="left">Implications for mitochondrial function</th>
<th align="left">References</th>
</tr>
</thead>
<tbody>
<tr>
<td rowspan="2" valign="top">Ca<sup>2+</sup></td>
<td rowspan="2" valign="top"><list id="list1-0004867412449303" list-type="order">
<list-item><p>Elevated levels in mitochondria leads to apoptosis and impaired ATP synthesis</p></list-item>
<list-item><p>D2 subunit of the L-type of the voltage-gated calcium channel</p></list-item></list></td>
<td rowspan="2" valign="top"><list id="list2-0004867412449303" list-type="order">
<list-item><p>Mitochondria regulate Ca<sup>2+</sup>; excessive Ca<sup>2+</sup> interferes with ability to export cations and protons</p></list-item>
<list-item><p>Dysregulation of Ca<sup>2+</sup> influx which increases energetic requirements</p></list-item></list></td>
<td><xref ref-type="bibr" rid="bibr27-0004867412449303">Bernardi et al., 1998</xref>; <xref ref-type="bibr" rid="bibr196-0004867412449303">Weeber et al., 2002</xref></td>
</tr>
<tr>
<td><xref ref-type="bibr" rid="bibr168-0004867412449303">Sklar et al., 2008</xref></td>
</tr>
<tr>
<td colspan="4"><hr/></td>
</tr>
<tr>
<td>pH Levels</td>
<td><list id="list3-0004867412449303" list-type="order">
<list-item><p>Lower intracellular pH levels</p></list-item>
<list-item><p>Lower pH in basal ganglia region and whole brain of euthymic BP versus NC</p></list-item></list></td>
<td>A metabolic shift towards anaerobic glycolysis for energy production leads to increased lactate levels and reduced pH levels</td>
<td><list id="list4-0004867412449303" list-type="order">
<list-item><p><xref ref-type="bibr" rid="bibr45-0004867412449303">Dager et al., 2004</xref>; <xref ref-type="bibr" rid="bibr123-0004867412449303">Ng et al., 2008</xref>; <xref ref-type="bibr" rid="bibr174-0004867412449303">Stork and Renshaw, 2005</xref></p></list-item>
<list-item><p><xref ref-type="bibr" rid="bibr71-0004867412449303">Hamakawa et al., 2004</xref></p></list-item></list></td>
</tr>
<tr>
<td colspan="4"><hr/></td>
</tr>
<tr>
<td><italic>N</italic>-acetyl-aspartate (NAA)/ phosphocreatine (PCr)</td>
<td><list id="list5-0004867412449303" list-type="order">
<list-item><p>BPI associated with decreased cerebral NAA in the right hippocampus vs NC</p></list-item>
<list-item><p>Regional reduction of NAA relative signals, suggesting neuronal damage of the hippocampus</p></list-item>
<list-item><p>PCr altered in BP; low PCr found in BPII versus NC in all three psychiatric states (hypomanic, euthymic, depressed)</p></list-item></list></td>
<td><list id="list6-0004867412449303" list-type="order">
<list-item><p>NAA is synthesized in mitochondria by the membrane-bound enzyme L-aspartate <italic>N</italic>-acetyltransferase, only found in brain</p></list-item>
<list-item><p>Decreased NAA are consistent with impaired mitochondrial energy production</p></list-item>
<list-item><p>PCr is a reservoir for ATP generation; breakdown to maintain ATP concentration levels; low levels associated with hypometabolism</p></list-item></list></td>
<td><list id="list7-0004867412449303" list-type="order">
<list-item><p><xref ref-type="bibr" rid="bibr48-0004867412449303">Deicken et al., 2003</xref></p></list-item>
<list-item><p><xref ref-type="bibr" rid="bibr29-0004867412449303">Bertolino et al., 2003</xref></p></list-item>
<list-item><p><xref ref-type="bibr" rid="bibr85-0004867412449303">Kato et al., 1994</xref>; <xref ref-type="bibr" rid="bibr84-0004867412449303">Kato et al., 1995</xref></p></list-item></list></td>
</tr>
<tr>
<td colspan="4"><hr/></td>
</tr>
<tr>
<td>Bcl-2</td>
<td><list id="list8-0004867412449303" list-type="order">
<list-item><p>Increased levels with lithium and/or valproic acid treatment</p></list-item></list></td>
<td><list id="list9-0004867412449303" list-type="order">
<list-item><p>Neuroprotetic and anti-apoptotic effect on mitochondria; increase resistance to toxic effects of elevated intracellular Ca<sup>2+</sup></p></list-item>
<list-item><p>Increases stability of the PTP</p></list-item></list></td>
<td><list id="list10-0004867412449303" list-type="order">
<list-item><p><xref ref-type="bibr" rid="bibr39-0004867412449303">Chen et al., 1999</xref>; <xref ref-type="bibr" rid="bibr108-0004867412449303">Manji et al., 2000</xref>; <xref ref-type="bibr" rid="bibr119-0004867412449303">Murphy et al., 1996</xref>; Perera et al., 2007</p></list-item>
<list-item><p><xref ref-type="bibr" rid="bibr196-0004867412449303">Weeber et al., 2002</xref></p></list-item></list></td>
</tr>
<tr>
<td colspan="4"><hr/></td>
</tr>
<tr>
<td>Effects of mood stabilizers</td>
<td><list id="list11-0004867412449303" list-type="order">
<list-item><p>Therapeutic doses of lithium and valproic acid increase levels of Bcl-2 in rats</p></list-item>
<list-item><p>Neuroprotective effects against oxidative damage from H<sub>2</sub>O<sub>2</sub></p></list-item></list></td>
<td><list id="list12-0004867412449303" list-type="order">
<list-item><p>Neuroprotective effects mediated by increasing GSH and GCL levels</p></list-item>
<list-item><p>Lithium increases gene expression of GST isoenzymes, neuroprotective; if GSH-depleted, neuroprotective effects destroyed</p></list-item></list></td>
<td><list id="list13-0004867412449303" list-type="order">
<list-item><p><xref ref-type="bibr" rid="bibr42-0004867412449303">Cui et al., 2007</xref></p></list-item>
<list-item><p><xref ref-type="bibr" rid="bibr159-0004867412449303">Shao et al., 2008a</xref></p></list-item></list></td>
</tr>
<tr>
<td colspan="4"><hr/></td>
</tr>
<tr>
<td>Mitochondrial gene expression</td>
<td><list id="list14-0004867412449303" list-type="order">
<list-item><p>SNPs ‘tag’ common mitochondrial variations that may be associated with differential treatment response</p></list-item>
<list-item><p>Val66met polymorphism of the BDNF gene is associated with rapid cycling</p></list-item></list></td>
<td><list id="list15-0004867412449303" list-type="order">
<list-item><p>Polymorphisms approximately 10 times more frequent in mitochondrial DNA versus autosomal DNA</p></list-item>
<list-item><p>Low levels of PCr + Cr in DLPFC suggests low bioenergetic metabolism; BDNF may be a neuroprotective factor for mitochondrial dysfunction</p></list-item></list></td>
<td><list id="list16-0004867412449303" list-type="order">
<list-item><p><xref ref-type="bibr" rid="bibr144-0004867412449303">Richter et al., 1988</xref>; <xref ref-type="bibr" rid="bibr158-0004867412449303">Saxena et al., 2006</xref></p></list-item>
<list-item><p><xref ref-type="bibr" rid="bibr57-0004867412449303">Frey et al., 2007b</xref>; <xref ref-type="bibr" rid="bibr116-0004867412449303">Müller et al., 2006</xref></p></list-item></list></td>
</tr>
<tr>
<td colspan="4"><hr/></td>
</tr>
<tr>
<td>Brain energy metabolism</td>
<td><list id="list17-0004867412449303" list-type="order">
<list-item><p>Decreased cerebral NAA, synthesized by brain-specific catalyst L-aspartate <italic>N</italic>-acetyltransferase</p></list-item>
<list-item><p>Decreased brain PCr levels</p></list-item></list></td>
<td><list id="list18-0004867412449303" list-type="order">
<list-item><p>Impaired mitochondrial energy production</p></list-item>
<list-item><p>Insufficient supply of ATP generated due to hypometabolism and possibly mitochondrial dysfunction</p></list-item></list></td>
<td><list id="list19-0004867412449303" list-type="order">
<list-item><p><xref ref-type="bibr" rid="bibr29-0004867412449303">Bertolino et al., 2003</xref>; <xref ref-type="bibr" rid="bibr40-0004867412449303">Clark, 1998</xref>; <xref ref-type="bibr" rid="bibr131-0004867412449303">Patel and Clark, 1979</xref></p></list-item>
<list-item><p><xref ref-type="bibr" rid="bibr85-0004867412449303">Kato et al., 1994</xref>; <xref ref-type="bibr" rid="bibr84-0004867412449303">Kato et al., 1995</xref></p></list-item></list></td>
</tr>
<tr>
<td colspan="4"><hr/></td>
</tr>
<tr>
<td>Abnormal mitochondrial structure and distribution</td>
<td><list id="list20-0004867412449303" list-type="order">
<list-item><p>Mitochondria of smaller area observed in postmortem brain tissue of bipolar disorder patients</p></list-item>
<list-item><p>Atypically shaped mitochondria observed in peripheral cells from bipolar disorder patients</p></list-item>
<list-item><p>Perinuclear clustering of mitochondria observed in peripheral cells from bipolar disorder patients</p></list-item></list></td>
<td><list id="list21-0004867412449303" list-type="order">
<list-item><p>Abnormal morphology and distribution of mitochondria may have significant effects on neuroplasticity and cell resilience and survival</p></list-item></list></td>
<td><list id="list22-0004867412449303" list-type="order">
<list-item><p><xref ref-type="bibr" rid="bibr37-0004867412449303">Cataldo et al., 2010</xref></p></list-item></list></td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-0004867412449303">
<p>ATP: adenosine-5′-triphosphate; DLPFC: dorsolateral prefrontal cortex; GCL: glutamate-cysteine ligase; GSH: glutathione; GST: glutathione-<italic>S</italic>-transferase; NC: normal controls; PTP: permeability transition pore; SNP: single nucleotide polymorphism.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<table-wrap id="table2-0004867412449303" position="float">
<label>Table 2.</label>
<caption>
<p>Potential mitochondrial modulators and their effects on mitochondria and oxidative stress.</p>
</caption>
<graphic alternate-form-of="table2-0004867412449303" xlink:href="10.1177_0004867412449303-table2.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup>
<thead>
<tr>
<th align="left" rowspan="2"/>
<th align="left" colspan="5">Electron transport chain<hr/></th>
<th align="left" rowspan="2">Effects on fatty acids</th>
<th align="left" rowspan="2">Effect on level of ROS</th>
<th align="left" rowspan="2">Clinical evidence in neurodegenerative disorder</th>
</tr>
<tr>
<th align="left">I</th>
<th align="left">II</th>
<th align="left">III</th>
<th align="left">IV</th>
<th align="left">V</th>
</tr>
</thead>
<tbody>
<tr>
<td><italic>N</italic>-acetyl-cysteine (NAC)</td>
<td>X</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>↓</td>
<td>NAC augmentation reduces negative symptoms and improved auditory processing in schizophrenia</td>
</tr>
<tr>
<td colspan="9"><hr/></td>
</tr>
<tr>
<td>Acetyl-L-carnitine (ALCAR)</td>
<td>X</td>
<td>X</td>
<td>–</td>
<td>X</td>
<td>–</td>
<td>Transports fatty acid into mitochondria for beta-oxidaton and energy generation</td>
<td>↓</td>
<td>Improves selective areas of cognition for Alzheimer’s disease, ADHD inattentive type (<xref ref-type="bibr" rid="bibr17-0004867412449303">Arnold et al., 2007</xref>)<break/>Improves fatigue and peripheral neuropathy associated with HIV infection</td>
</tr>
<tr>
<td colspan="9"><hr/></td>
</tr>
<tr>
<td><italic>S</italic>-adenosyl-methionine (SAMe)</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>↓</td>
<td>Reduces severity of depression (e.g. CGI, HAM-D scores) when added to SSRI antidepressants or venlafaxine (<xref ref-type="bibr" rid="bibr8-0004867412449303">Alpert, 2004</xref>)</td>
</tr>
<tr>
<td colspan="9"><hr/></td>
</tr>
<tr>
<td>CoQ10</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>↓</td>
<td>Reduced functional decline of untreated, early Parkinson’s disease at 1200 mg/day (<xref ref-type="bibr" rid="bibr165-0004867412449303">Shultz, 2002</xref>)<break/>Tolerated at high doses (Shultz, 2008)<break/>Decreased elevated lactate levels of the basal ganglia and increased complex I activity in Huntington’s disease (<xref ref-type="bibr" rid="bibr53-0004867412449303">Feigin et al., 1996</xref>)</td>
</tr>
<tr>
<td colspan="9"><hr/></td>
</tr>
<tr>
<td>Alpha-lipoic acid (ALA)</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>↓</td>
<td>Significantly slowed the increase of hepatocellular oxidants, MDA levels, and lipid peroxidation in old rats (<xref ref-type="bibr" rid="bibr66-0004867412449303">Hagen, 1999</xref>)<break/>Reversed the age-related decline of intracellular GSH and ascorbic acid levels (<xref ref-type="bibr" rid="bibr66-0004867412449303">Hagen, 1999</xref>)</td>
</tr>
<tr>
<td colspan="9"><hr/></td>
</tr>
<tr>
<td>Creatine</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>↓</td>
<td>Oral consumption of CM can increase brain creatine and PCr concentrations (<xref ref-type="bibr" rid="bibr46-0004867412449303">Dechent et al., 1999</xref>; <xref ref-type="bibr" rid="bibr104-0004867412449303">Lyoo et al., 2003</xref>)</td>
</tr>
<tr>
<td colspan="9"><hr/></td>
</tr>
<tr>
<td>Melatonin</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>–</td>
<td>–</td>
<td>↓</td>
<td>Improved sleep in individuals with seasonal affective disorder (<xref ref-type="bibr" rid="bibr97-0004867412449303">Leppamaki et al., 2003</xref>)<break/>Open-label administration had sleep-enhancing and antimanic effects in bipolar patients, with no effects on mood or sleep (<xref ref-type="bibr" rid="bibr28-0004867412449303">Bersani and Garavini, 2000</xref>)<break/>Resulted in a significant reduction of depression symptoms compared to placebo in patients with ‘winter depression’ (<xref ref-type="bibr" rid="bibr98-0004867412449303">Lewy et al., 1998</xref>)</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn2-0004867412449303">
<p>ADHD: attention deficit disorder; CGI: Clinical Global Impression Scale; CM: creatine monohydrate; GSH: glutathione; HAM-D: Hamilton Depression Rating Scale; MDA: malondialdehyde; PCr: phosphocreatine; ROS: reactive oxygen species; SSRI: selective serotonin re-uptake inhibitor.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>Evidence of CoQ10’s role in oxidative stress suggests that oral administration of coenzyme Q10 has the potential to be part of the treatment of such neurodegenerative diseases. For example, individuals with Huntington’s disease showed a decrease in elevated lactate levels in the basal ganglia, as well as an increase in complex I activity after treatment with CoQ10 (<xref ref-type="bibr" rid="bibr53-0004867412449303">Feigin et al., 1996</xref>). Patients with early, untreated Parkinson’s disease showed a slower decline in functioning when CoQ10 was given at a dose of 1200 mg/day (<xref ref-type="bibr" rid="bibr165-0004867412449303">Shults et al., 2002</xref>), a dose that has been found to have a good safety profile (<xref ref-type="bibr" rid="bibr75-0004867412449303">Hidaka et al., 2008</xref>). A more recent study investigating a higher dosage of CoQ10 in conjunction with vitamin E suggested that CoQ10 is safe and tolerated at doses up to 3000 mg/day for 2 weeks, but should not exceed 2400 mg/day since any dosage beyond this amount does not increase plasma levels of alpha-tocopherol (<xref ref-type="bibr" rid="bibr163-0004867412449303">Shults et al., 2004</xref>). Other evidence found that while CoQ10 supplementation increased plasma levels of CoQ10 in patients with Parkinson’s disease, it had no effect on Parkinsonian symptoms after a 3-month period (<xref ref-type="bibr" rid="bibr173-0004867412449303">Storch et al., 2007</xref>). Similarly, in an open label trial of 200 mg of daily CoQ10 supplementation, idiopathic parkinsonian patients demonstrated no significant clinical effect in a 3-month period (<xref ref-type="bibr" rid="bibr175-0004867412449303">Strijks et al., 1997</xref>).</p>
<p>Clinical trials of CoQ10 in other health conditions also indicate evidence of clinical improvement with CoQ10 supplementation. In a recent meta-analysis of 12 clinical trials of the efficacy of CoQ10 supplementation in hypertensive patients, it was suggested that CoQ10 may lower both systolic blood pressure and diastolic blood pressure (<xref ref-type="bibr" rid="bibr149-0004867412449303">Rosenfeldt et al., 2007</xref>). A 3-month supplementation of CoQ10 in patients with migraine showed a reduction in the frequency and disability of headaches (<xref ref-type="bibr" rid="bibr74-0004867412449303">Hershey et al., 2007</xref>). Similarly, individuals randomized to CoQ10 supplementation (300 mg/day) in a double-blind, randomized, placebo-controlled trial showed improvement in symptoms of migraine including reduced attack-frequency, reduced nausea and vomiting associated with migraine, and fewer headache days over a 4-month period (<xref ref-type="bibr" rid="bibr154-0004867412449303">Sandor et al., 2005</xref>). Such evidence suggests that the level of CoQ10 may be helpful in both understanding and treating disorders related to dysfunctional energy metabolism, particularly mood disorders. To our knowledge, no clinical trials have been completed that have investigated the clinical value of CoQ10 for individuals with major depressive disorder, bipolar disorder, or anxiety disorders.</p>
</sec>
<sec id="section17-0004867412449303">
<title>Alpha-lipoic acid (ALA)</title>
<p>Alpha-lipoic acid (ALA) is a naturally occurring mitochondrial coenzyme for pyruvate and alpha-ketoglutarate dehydrogenase. It is a potent antioxidant (<xref ref-type="bibr" rid="bibr127-0004867412449303">Packer et al., 1995</xref>) and carries out an essential role in mitochondrial energy production by recruiting glucose transporters to the cell membrane, thereby increasing the cellular uptake of glucose for ATP synthesis (<xref ref-type="bibr" rid="bibr52-0004867412449303">Estrada et al., 1996</xref>).</p>
<p>ALA can be obtained through diet in foods such as spinach, yeast and red meats, and has been shown to have antioxidant properties when administered as a dietary supplement to increase the unbound fraction of the compound. Both in vitro and in vivo studies of ALA supplementation have demonstrated potent antioxidant effects (<xref ref-type="bibr" rid="bibr127-0004867412449303">Packer et al., 1995</xref>). For example, one study found that ALA supplementation slowed the increase of hepatocellular oxidants, malondialdehyde (MDA) levels and lipid peroxidation in old rats, and reversed the age-related decline of intracellular GSH and ascorbic acid levels (<xref ref-type="bibr" rid="bibr66-0004867412449303">Hagen et al., 1999</xref>).</p>
<p>In addition to improving cellular antioxidant status, ALA has been shown to reverse metabolic deficits, oxidative stress, and damage associated with aging when administered as a dietary supplement (<xref ref-type="bibr" rid="bibr65-0004867412449303">Hagen et al., 2002a</xref>). Moreover, ALA has been shown to effectively reduce oxidative stress and ameliorate energy-related metabolic impairments, specifically in type II diabetes, liver disease or age-related oxidative damage (<xref ref-type="bibr" rid="bibr65-0004867412449303">Hagen et al., 2002a</xref>). Specifically, high-dose ALA administered intravenously to diabetic and control rats induced a rapid reduction of blood glucose levels and acetyl CoA content in the liver (<xref ref-type="bibr" rid="bibr151-0004867412449303">Rudich et al., 1999</xref>), and oral doses of ALA lowered elevated hepatic and cerebral malondialdehyde levels of older rats (<xref ref-type="bibr" rid="bibr67-0004867412449303">Hagen et al., 2002b</xref>).</p>
<p>ALA supplementation has also demonstrated neuroprotective effects against peripheral oxidative stress and damage from <sc>d</sc>-galactose exposure (<xref ref-type="bibr" rid="bibr43-0004867412449303">Cui et al., 2006</xref>). Toxic levels of <sc>d</sc>-galactose induced several neurobiological changes in mice, rats, and <italic>Drosophilia</italic>, including inhibited neural progenitor cell migration, enhanced caspase-mediated cell apoptosis and decreased total antioxidative capability (T-AOC), MDA and glutathione peroxidase (GSH-Px) activities. Treatment with ALA reversed this oxidative damage, which subsequently improved cognitive function, slowed hippocampal neurodegeneration and reversed oxidative damage (<xref ref-type="bibr" rid="bibr43-0004867412449303">Cui et al., 2006</xref>).</p>
<p>ALA has been investigated as a potential treatment in a number of diseases thought to be associated with abnormal mitochondrial functioning and impaired energy utilization, including type II diabetes (<xref ref-type="bibr" rid="bibr77-0004867412449303">Jacob et al., 1999</xref>) and diabetic polyneuropathy (<xref ref-type="bibr" rid="bibr12-0004867412449303">Ametov et al., 2003</xref>; <xref ref-type="bibr" rid="bibr69-0004867412449303">Hahm et al., 2004</xref>; <xref ref-type="bibr" rid="bibr122-0004867412449303">Negrisanu et al., 1999</xref>; <xref ref-type="bibr" rid="bibr143-0004867412449303">Reljanovic et al., 1999</xref>; <xref ref-type="bibr" rid="bibr152-0004867412449303">Ruhnau et al., 1999</xref>; <xref ref-type="bibr" rid="bibr180-0004867412449303">Tankova et al., 2004</xref>; <xref ref-type="bibr" rid="bibr205-0004867412449303">Ziegler et al., 1995</xref>, <xref ref-type="bibr" rid="bibr206-0004867412449303">1999</xref>, <xref ref-type="bibr" rid="bibr204-0004867412449303">2006</xref>). It has also been studied in the treatment of alcohol-related liver disease (<xref ref-type="bibr" rid="bibr109-0004867412449303">Marshall et al., 1982</xref>), burning mouth syndrome (<xref ref-type="bibr" rid="bibr54-0004867412449303">Femiano and Scully, 2002</xref>), diabetes-related cardiac autonomic neuropathy (<xref ref-type="bibr" rid="bibr207-0004867412449303">Ziegler et al., 1997</xref>), HIV-associated cognitive impairment (<xref ref-type="bibr" rid="bibr16-0004867412449303">Anonymous, 1998</xref>), multiple sclerosis (<xref ref-type="bibr" rid="bibr199-0004867412449303">Yadav et al., 2005</xref>), migraine (<xref ref-type="bibr" rid="bibr105-0004867412449303">Magis et al., 2007</xref>), peripheral arterial disease (<xref ref-type="bibr" rid="bibr192-0004867412449303">Vincent et al., 2007</xref>) and Alzheimer’s disease (<xref ref-type="bibr" rid="bibr68-0004867412449303">Hager et al., 2007</xref>).</p>
<p>Although the specific mechanism by which ALA improves mitochondrial function has not been identified, several have been discussed in the literature including: (1) increased recycling of endogenous antioxidants including CoQ10, vitamins C and E, and GSH (<xref ref-type="bibr" rid="bibr100-0004867412449303">Liu, 2008</xref>); (2) reduction to the highly potent antioxidant dihydrolipoic acid which reacts with superoxide radicals, hypochlorous acid, peroxyl radicals, and singlet oxygen (<xref ref-type="bibr" rid="bibr101-0004867412449303">Liu et al., 2002a</xref>); (3) chelation of heavy metals such as iron and copper (<xref ref-type="bibr" rid="bibr100-0004867412449303">Liu, 2008</xref>); (4) stimulation of glucose uptake into cells leading to enhanced energy metabolism (<xref ref-type="bibr" rid="bibr52-0004867412449303">Estrada et al., 1996</xref>); (5) anti-apoptotic and neuroprotective effects secondary to prevention of glutamate-induced increases in intracellular calcium (<xref ref-type="bibr" rid="bibr100-0004867412449303">Liu, 2008</xref>; <xref ref-type="bibr" rid="bibr101-0004867412449303">Liu et al., 2002a</xref>); and (6) stimulation of mitochondrial biogenesis through upregulation of mitochondrial transcription factors such as peroxisome proliferator-activated receptor-gamma coactivator-1α (PGC-1α) (<xref ref-type="bibr" rid="bibr100-0004867412449303">Liu, 2008</xref>).</p>
</sec>
<sec id="section18-0004867412449303">
<title>Creatine monohydrate (CM)</title>
<p>Creatine is a non-essential dietary element that is found in meat and fish and is synthesized endogenously by the liver and kidneys (<xref ref-type="bibr" rid="bibr79-0004867412449303">Juhn and Tarnopolsky, 1998</xref>; <xref ref-type="bibr" rid="bibr187-0004867412449303">Terjung et al., 2000</xref>). Exogenous creatine is widely available as a dietary supplement in the form of creatine monohydrate (CM).</p>
<p>Creatine is the precursor of PCr, which plays an integral role in brain and muscle energy metabolism. The primary role of PCr is to function as a reservoir of inorganic phosphate to be drawn upon to produce ATP by the catalyzing agent creatine kinase (<xref ref-type="bibr" rid="bibr10-0004867412449303">Ames, 2000</xref>). During periods of transient high-energy demands, PCr is rapidly converted to creatine in order to donate a high-energy phosphate to adenosine diphosphate (ADP) to maintain the overall intracellular concentration of ATP (<xref ref-type="bibr" rid="bibr51-0004867412449303">Erecinska and Silver, 1989</xref>; <xref ref-type="bibr" rid="bibr157-0004867412449303">Sauter and Rudin, 1993</xref>). While short-term decreases in PCr may reflect typical physiologic responses to acute muscular or neuronal activity, long-term abnormalities in PCr generally reflect an insufficient metabolic supply of ATP needed for normal cellular function, possibly due to underlying mitochondrial dysfunction, leading to deficits in oxidative phosphorylation (<xref ref-type="bibr" rid="bibr150-0004867412449303">Rothman, 1994</xref>). This concept is reflected in studies of patients with mitochondrial cytopathies, in which reduced brain PCr concentrations have been observed (<xref ref-type="bibr" rid="bibr20-0004867412449303">Barbiroli et al., 1993</xref>). Decreased PCr concentrations have also been identified in patients with bipolar disorder (<xref ref-type="bibr" rid="bibr174-0004867412449303">Stork and Renshaw, 2005</xref>). Notably, several studies have shown that oral consumption of CM can increase brain creatine and PCr concentrations (<xref ref-type="bibr" rid="bibr46-0004867412449303">Dechent et al., 1999</xref>; <xref ref-type="bibr" rid="bibr104-0004867412449303">Lyoo et al., 2003</xref>), suggesting that CM supplementation may mitigate bioenergetic abnormalities by providing additional substrate for the production of ATP through the creatine kinase reaction.</p>
<p>In addition to enhancing energy production, creatine has been shown to have direct and indirect antioxidant properties (<xref ref-type="bibr" rid="bibr93-0004867412449303">Lawler et al., 2002</xref>; <xref ref-type="bibr" rid="bibr181-0004867412449303">Tarnopolsky, 2008</xref>; <xref ref-type="bibr" rid="bibr182-0004867412449303">Tarnopolsky and Beal, 2001</xref>). For example, creatine has been shown to reduce markers of oxidative stress in animal models of Huntington’s disease (<xref ref-type="bibr" rid="bibr15-0004867412449303">Andreassen et al., 2001</xref>) and amyotrophic lateral sclerosis (ALS) (<xref ref-type="bibr" rid="bibr87-0004867412449303">Klivenyi et al., 1999</xref>). Moreover, creatine supplementation was found to have indirect antioxidant properties in an animal model of traumatic brain injury that were associated with reduced apoptosis, prevention of opening of the MPTP, and better maintenance of the mitochondrial membrane potential (<xref ref-type="bibr" rid="bibr93-0004867412449303">Lawler et al., 2002</xref>; <xref ref-type="bibr" rid="bibr176-0004867412449303">Sullivan et al., 2000</xref>).</p>
<p>Several clinical trials with CM in the treatment of mitochondrial cytopathies (<xref ref-type="bibr" rid="bibr184-0004867412449303">Tarnopolsky et al., 1997</xref>), neuromuscular disorders (<xref ref-type="bibr" rid="bibr183-0004867412449303">Tarnopolsky et al., 2004</xref>; <xref ref-type="bibr" rid="bibr194-0004867412449303">Walter et al., 2000</xref>) and neurodegenerative disorders such as Parkinson’s disease (<xref ref-type="bibr" rid="bibr22-0004867412449303">Bender et al., 2006</xref>; <xref ref-type="bibr" rid="bibr126-0004867412449303">NINDS NET-PD Investigators, 2006</xref>), Huntington’s disease (<xref ref-type="bibr" rid="bibr178-0004867412449303">Tabrizi et al., 2005</xref>; <xref ref-type="bibr" rid="bibr190-0004867412449303">Verbessem et al., 2003</xref>) and ALS (<xref ref-type="bibr" rid="bibr64-0004867412449303">Groeneveld et al., 2003</xref>; <xref ref-type="bibr" rid="bibr148-0004867412449303">Rosenfeld et al., 2008</xref>) have been performed with mixed results. CM supplementation demonstrated benefit in one small, open-label study in patients with post-traumatic stress disorder (PTSD) (<xref ref-type="bibr" rid="bibr13-0004867412449303">Amital et al., 2006a</xref>) and was associated with improvement in depression symptoms in a patient with comorbid depression and fibromyalgia (<xref ref-type="bibr" rid="bibr14-0004867412449303">Amital et al., 2006b</xref>). In contrast, there was no evidence of efficacy following CM treatment in a small controlled trial in schizophrenia (<xref ref-type="bibr" rid="bibr81-0004867412449303">Kaptsan et al., 2007</xref>). A small open-label study suggested a beneficial effect of CM augmentation in patients with treatment-resistant depression (<xref ref-type="bibr" rid="bibr147-0004867412449303">Roitman et al., 2007</xref>). Interestingly, this study enrolled two bipolar depressed patients – both of whom developed hypomania/mania after CM treatment. All in all, preclinical and clinical evidence to date encourages further exploration of the potential benefit of CM supplementation in disorders associated with mitochondrial dysfunction, including bipolar disorder.</p>
</sec>
<sec id="section19-0004867412449303">
<title>Melatonin</title>
<p>Melatonin was long conceived as a hormone secreted in a tightly regulated circadian rhythm by the pineal gland, which served a primary role in reproduction. However, the recent recognition that melatonin is synthesized in many organs and tissues in the body, including the brain, has sparked exploration into its potential role in a variety of physiological processes.</p>
<p>Growing evidence suggests that melatonin has potent antioxidant properties that result from direct free radical scavenging properties as well as effects on mitochondrial physiology. Several studies have demonstrated that melatonin and several of its metabolites are major scavengers of both oxygen- and nitrogen-based ROS (<xref ref-type="bibr" rid="bibr89-0004867412449303">Korkmaz et al., 2009</xref>; <xref ref-type="bibr" rid="bibr103-0004867412449303">Lopez-Burillo et al., 2003</xref>; <xref ref-type="bibr" rid="bibr140-0004867412449303">Reiter et al., 2002a</xref>, <xref ref-type="bibr" rid="bibr141-0004867412449303">2002b</xref>, <xref ref-type="bibr" rid="bibr142-0004867412449303">2003</xref>), and melatonin has been shown to stimulate the production of GSH (<xref ref-type="bibr" rid="bibr5-0004867412449303">Albarran et al., 2001</xref>; <xref ref-type="bibr" rid="bibr198-0004867412449303">Winiarska et al., 2006</xref>). Interestingly, melatonin has also been shown to have direct genomic effects. For example, melatonin increases the mRNA expression of genes involved in antioxidant production such as glutathione peroxidase and superoxide dismutase (SOD) under physiological conditions and during elevated oxidative stress (<xref ref-type="bibr" rid="bibr3-0004867412449303">Acuna-Castroviejo et al., 2007</xref>; <xref ref-type="bibr" rid="bibr145-0004867412449303">Rodriguez et al., 2004</xref>; <xref ref-type="bibr" rid="bibr179-0004867412449303">Tan et al., 1998</xref>).</p>
<p>In addition to its antioxidant effects, evidence suggests that melatonin may have a direct benefit on mitochondrial functioning. Both in vitro and in vivo animal studies have demonstrated multiple mitochondrial enhancing effects following melatonin administration, including increased oxidative phosphorylation through activation of ETC complexes, increased mitochondrial membrane fluidity, and closing of the MPTP (<xref ref-type="bibr" rid="bibr4-0004867412449303">Acuna-Castroviejo et al., 2001</xref>, <xref ref-type="bibr" rid="bibr3-0004867412449303">2007</xref>; <xref ref-type="bibr" rid="bibr59-0004867412449303">Garcia et al., 1997</xref>; <xref ref-type="bibr" rid="bibr96-0004867412449303">Leon et al., 2004</xref>, <xref ref-type="bibr" rid="bibr95-0004867412449303">2005</xref>). Moreover, melatonin has direct effects on mitochondrial genome expression. For example, studies have shown that melatonin administration prevents oxidative degradation of mtDNA and reduction of mtDNA transcripts in several tissues including brain (<xref ref-type="bibr" rid="bibr2-0004867412449303">Acuna-Castroviejo et al., 2005</xref>) and increases expression of mtDNA-coded polypeptide subunits I, II and III of ETC complex IV (<xref ref-type="bibr" rid="bibr1-0004867412449303">Acuna-Castroviejo et al., 2003</xref>).</p>
<p>Recent exploration into the potential clinical utility of melatonin, primarily in the treatment of neurodegenerative disorders hypothesized to result, in part, from mitochondrial dysfunction, has provided some encouraging results. Melatonin prevented neurodegenerative changes in several experimental models of Alzheimer’s disease (<xref ref-type="bibr" rid="bibr92-0004867412449303">Lahiri et al., 2004</xref>; <xref ref-type="bibr" rid="bibr129-0004867412449303">Pappolla et al., 1998</xref>; <xref ref-type="bibr" rid="bibr139-0004867412449303">Reiter et al., 1999</xref>) and Huntington’s disease (<xref ref-type="bibr" rid="bibr139-0004867412449303">Reiter et al., 1999</xref>). Furthermore, preliminary studies in Alzheimer’s disease patients have demonstrated a slowing of cognitive impairment and a reduction in sundowning following melatonin treatment (<xref ref-type="bibr" rid="bibr34-0004867412449303">Cardinali et al., 2002</xref>). In addition, melatonin has demonstrated neuroprotective properties in animal models of Parkinson’s disease hypothesized to result from ROS scavenging, enhancement of ETC activity and increased mitochondrial membrane potential (<xref ref-type="bibr" rid="bibr3-0004867412449303">Acuna-Castroviejo et al., 2007</xref>; <xref ref-type="bibr" rid="bibr139-0004867412449303">Reiter et al., 1999</xref>).</p>
<p>Several small studies have evaluated the effect of melatonin administration in mood disorders with mixed results. A controlled study of melatonin in seasonal affective disorder demonstrated improvement in sleep and vitality, but no reduction in atypical depression symptoms (<xref ref-type="bibr" rid="bibr97-0004867412449303">Leppamaki et al., 2003</xref>). Patients with ‘winter depression’ demonstrated significantly reduced depression symptoms following melatonin treatment compared to placebo (<xref ref-type="bibr" rid="bibr98-0004867412449303">Lewy et al., 1998</xref>). In contrast, melatonin was associated with worsening dysphoria and reduced sleep and weight in a crossover study in patients with severe depression (<xref ref-type="bibr" rid="bibr35-0004867412449303">Carman et al., 1976</xref>). With regard to bipolar disorder, open-label melatonin had no significant effects on mood or sleep in a small study of rapid-cycling bipolar disorder (<xref ref-type="bibr" rid="bibr94-0004867412449303">Leibenluft et al., 1997</xref>) but was found to have sleep-enhancing and antimanic effects in a small open-label study in bipolar mania (<xref ref-type="bibr" rid="bibr28-0004867412449303">Bersani and Garavini, 2000</xref>).</p>
<p>Interestingly, agomelatine, a potent agonist of melatonin MT1 and MT2 receptors, has demonstrated preliminary evidence of efficacy in bipolar depression (<xref ref-type="bibr" rid="bibr33-0004867412449303">Calabrese et al., 2007</xref>). However, the antioxidant and mitochondrial-enhancing properties of melatonin are speculated to result primarily from direct free radical scavenging and actions linked to cytosolic proteins rather than receptor-mediated mechanisms (<xref ref-type="bibr" rid="bibr3-0004867412449303">Acuna-Castroviejo et al., 2007</xref>). Nevertheless, further exploration into the potential for melatonin-receptor modulators to enhance mitochondrial functioning is warranted.</p>
</sec>
</sec>
<sec id="section20-0004867412449303">
<title>Rationale for considering combinations of mitochondrial modulators</title>
<p>While convergent data strongly support the hypothesis that mitochondrial dysfunction occurs in bipolar disorder, multiple abnormalities along the mitochondrial ETC can occur, making it improbable that, for any given patient, the correct abnormality can be practically identified with currently available technology. In addition, while compounds such as ALCAR, SAMe and CM may increase energy production, this increase may also cause an increase in the production of ROS (<xref ref-type="bibr" rid="bibr65-0004867412449303">Hagen et al., 2002a</xref>). Mitochondrial DNA lack histones and are therefore extremely susceptible to damage from ROS. This feature sets up a vicious cycle in which increased ROS generation leads to further damage to mitochondrial DNA, proteins and lipids, which can further exacerbate defects in mitochondrial energy production.</p>
<p>Therefore, effective mitochondrial enhancement strategies may require several agents that both modulate multiple mitochondrial targets and increase mitochondrial metabolic activity without a concomitant increase in oxidative stress – a strategy that has been proposed previously in the treatment of mitochondrial disorders (<xref ref-type="bibr" rid="bibr146-0004867412449303">Rodriguez et al., 2007</xref>; <xref ref-type="bibr" rid="bibr181-0004867412449303">Tarnopolsky, 2008</xref>).</p>
<p>This ‘mitochondrial cocktail’ could include several of the agents described above. For example, whereas NAC targets complex I in the ETC and reduces oxidative stress, ALCAR targets complexes I, II and IV, as well as enhancing oxidation of fatty acids. Therefore, we reason that the combination treatment of NAC with ALCAR is more likely to modulate multiple mitochondrial targets while mitigating the resulting oxidative stress from ALCAR-induced mitochondrial energy production (<xref ref-type="bibr" rid="bibr65-0004867412449303">Hagen et al., 2002a</xref>) by increasing GSH via NAC supplementation. One study found improved cognitive functions and decreased aggression after treatment with a combination of NAC, ALCAR and SAMe in mouse models (<xref ref-type="bibr" rid="bibr161-0004867412449303">Shea, 2007</xref>), providing support for this strategy.</p>
<p>Given the enhancing effects of ALCAR on cerebral energy metabolism and the potent antioxidant properties of ALA, we theorize that a combination of ALCAR and ALA might also be effective in increasing mitochondrial metabolic activity without a concomitant increase in oxidative stress – as others have proposed (<xref ref-type="bibr" rid="bibr65-0004867412449303">Hagen et al., 2002a</xref>; <xref ref-type="bibr" rid="bibr169-0004867412449303">Soczynska et al., 2008</xref>). Animal studies have demonstrated that the combination treatment of ALCAR and ALA improves mitochondrial functioning by increasing metabolism and lowering oxidative stress more than either compound alone (<xref ref-type="bibr" rid="bibr65-0004867412449303">Hagen et al., 2002a</xref>; <xref ref-type="bibr" rid="bibr101-0004867412449303">Liu et al., 2002a</xref>, <xref ref-type="bibr" rid="bibr102-0004867412449303">2002b</xref>), providing preclinical support for this rationale.</p>
<p>The aim of this review is to support the rationale for rigorous studies of MMs (and combinations) in bipolar disorder. While clinicians could recommend such treatments currently, rigorous data are lacking in most instances to do so. Of note, combinations of MMs are likely to be well tolerated. For all the individual dietary supplements reviewed here, the available literature suggests adequate tolerability and low side-effect burden. While some of these dietary supplements can be costly (and none is reimbursed by insurance), it is unlikely that cost considerations will limit the availability of such treatments, especially after proof of clinical efficacy that will be obtained through rigorous clinical trials.</p>
</sec>
<sec id="section21-0004867412449303">
<title>Summary</title>
<p>While mitochondrial disorders can present in any system, the central nervous system is particularly vulnerable to dysregulations of mitochondrial function since it has high energy demands. Because convergent data implicate subtle mitochondrial dysfunctions as an important component of the pathophysiology of bipolar disorder, it makes sense to consider clinical trials of substances that have the potential to ameliorate those dysfunctions. We reviewed reasonable candidates for modulating mitochondrial function: <italic>N</italic>-acetyl-cysteine (NAC), acetyl-L-carnitine (ALCAR), <italic>S</italic>-adenosylmethionine (SAMe), coenzyme Q<sub>10</sub> (CoQ10), alpha-lipoic acid (ALA), creatine monohydrate (CM) and melatonin, and postulated that combinations of two or even more of these MMs could be of interest. These MMs should be considered for evaluation in rigorous, well-designed, well-powered clinical trials to improve the long-term course of bipolar disorder.</p>
</sec>
</body>
<back>
<fn-group>
<fn fn-type="financial-disclosure">
<label>Funding</label>
<p>This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.</p>
</fn>
<fn fn-type="conflict">
<label>Declaration of interest</label>
<p>The authors report no conflicts of interest. The authors alone are responsible for the content and writing of the paper.</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-0004867412449303">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Acuna-Castroviejo</surname><given-names>D</given-names></name>
<name><surname>Escames</surname><given-names>G</given-names></name>
<name><surname>Leon</surname><given-names>J</given-names></name>
<etal/>
</person-group>. (<year>2003</year>) <article-title>Mitochondrial regulation by melatonin and its metabolites</article-title>. <source>Advances in Experimental Medicine and Biology</source> <volume>527</volume>: <fpage>549</fpage>–<lpage>557</lpage>.</citation>
</ref>
<ref id="bibr2-0004867412449303">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Acuna-Castroviejo</surname><given-names>D</given-names></name>
<name><surname>Escames</surname><given-names>G</given-names></name>
<name><surname>Lopez</surname><given-names>LC</given-names></name>
<etal/>
</person-group>. (<year>2005</year>) <article-title>Melatonin and nitric oxide: Two required antagonists for mitochondrial homeostasis</article-title>. <source>Endocrine</source> <volume>27</volume>: <fpage>159</fpage>–<lpage>168</lpage>.</citation>
</ref>
<ref id="bibr3-0004867412449303">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Acuna-Castroviejo</surname><given-names>D</given-names></name>
<name><surname>Escames</surname><given-names>G</given-names></name>
<name><surname>Rodriguez</surname><given-names>MI</given-names></name>
<etal/>
</person-group>. (<year>2007</year>) <article-title>Melatonin role in the mitochondrial function</article-title>. <source>Frontiers in Bioscience</source> <volume>12</volume>: <fpage>947</fpage>–<lpage>963</lpage>.</citation>
</ref>
<ref id="bibr4-0004867412449303">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Acuna-Castroviejo</surname><given-names>D</given-names></name>
<name><surname>Martin</surname><given-names>M</given-names></name>
<name><surname>Macias</surname><given-names>M</given-names></name>
<etal/>
</person-group>. (<year>2001</year>) <article-title>Melatonin, mitochondria, and cellular bioenergetics</article-title>. <source>Journal of Pineal Research</source> <volume>30</volume>: <fpage>65</fpage>–<lpage>74</lpage>.</citation>
</ref>
<ref id="bibr5-0004867412449303">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Albarran</surname><given-names>MT</given-names></name>
<name><surname>Lopez-Burillo</surname><given-names>S</given-names></name>
<name><surname>Pablos</surname><given-names>MI</given-names></name>
<etal/>
</person-group>. (<year>2001</year>) <article-title>Endogenous rhythms of melatonin, total antioxidant status and superoxide dismutase activity in several tissues of chick and their inhibition by light</article-title>. <source>Journal of Pineal Research</source> <volume>30</volume>: <fpage>227</fpage>–<lpage>233</lpage>.</citation>
</ref>
<ref id="bibr6-0004867412449303">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Aliev</surname><given-names>G</given-names></name>
<name><surname>Liu</surname><given-names>J</given-names></name>
<name><surname>Shenk</surname><given-names>JC</given-names></name>
<etal/>
</person-group>. (<year>2009</year>) <article-title>Neuronal mitochondrial amelioration by feeding acetyl-L-carnitine and lipoic acid to aged rats</article-title>. <source>Journal of Cellular and Molecular Medicine</source> <volume>13</volume>: <fpage>320</fpage>–<lpage>333</lpage>.</citation>
</ref>
<ref id="bibr7-0004867412449303">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Al-Majed</surname><given-names>AA</given-names></name>
<name><surname>Sayed-Ahmed</surname><given-names>MM</given-names></name>
<name><surname>Al-Omar</surname><given-names>FA</given-names></name>
<etal/>
</person-group>. (<year>2006</year>) <article-title>Carnitine esters prevent oxidative stress damage and energy depletion following transient forbrain ischaemia in the rat hippocampus</article-title>. <source>Clinical and Experimental Pharmacology and Physiology</source> <volume>33</volume>: <fpage>725</fpage>–<lpage>733</lpage>.</citation>
</ref>
<ref id="bibr8-0004867412449303">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Alpert</surname><given-names>JE</given-names></name>
<name><surname>Papakostas</surname><given-names>G</given-names></name>
<name><surname>Mischoulon</surname><given-names>D</given-names></name>
<etal/>
</person-group>. (<year>2004</year>) <article-title><italic>S</italic>-adenosyl-L-methionine (SAMe) as an adjunct for resistant major depressive disorder – An open trial following partial or nonresponse to selective serotonin reuptake inhibitors or venlafaxine</article-title>. <source>Journal of Clinical Psychopharmacology</source> <volume>24</volume>: <fpage>661</fpage>–<lpage>664</lpage>.</citation>
</ref>
<ref id="bibr9-0004867412449303">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Alvarez</surname><given-names>E</given-names></name>
<name><surname>Udina</surname><given-names>C</given-names></name>
<name><surname>Guillamat</surname><given-names>R</given-names></name>
</person-group> (<year>1987</year>) <article-title>Shortening of latency period in depressed patients treated with SAMe and other antidepressant drugs</article-title>. <source>Cellular Biological Review</source> <volume>S1</volume>: <fpage>103</fpage>–<lpage>110</lpage>.</citation>
</ref>
<ref id="bibr10-0004867412449303">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ames</surname><given-names>A</given-names><suffix>3rd</suffix></name>
</person-group> (<year>2000</year>) <article-title>CNS energy metabolism as related to function</article-title>. <source>Brain Research. Brain Research Reviews</source> <volume>34</volume>: <fpage>42</fpage>–<lpage>68</lpage>.</citation>
</ref>
<ref id="bibr11-0004867412449303">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ames</surname><given-names>BN</given-names></name>
<name><surname>Liu</surname><given-names>J</given-names></name>
</person-group> (<year>2004</year>) <article-title>Delaying the mitochondrial decay of aging with acetylcarnitine</article-title>. <source>Annals of the New York Academy of Sciences</source> <volume>1033</volume>: <fpage>108</fpage>–<lpage>116</lpage>.</citation>
</ref>
<ref id="bibr12-0004867412449303">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ametov</surname><given-names>AS</given-names></name>
<name><surname>Barinov</surname><given-names>A</given-names></name>
<name><surname>Dyck</surname><given-names>PJ</given-names></name>
<etal/>
</person-group>. (<year>2003</year>) <article-title>The sensory symptoms of diabetic polyneuropathy are improved with alpha-lipoic acid: The SYDNEY trial</article-title>. <source>Diabetes Care</source> <volume>26</volume>: <fpage>770</fpage>–<lpage>776</lpage>.</citation>
</ref>
<ref id="bibr13-0004867412449303">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Amital</surname><given-names>D</given-names></name>
<name><surname>Vishne</surname><given-names>T</given-names></name>
<name><surname>Roitman</surname><given-names>S</given-names></name>
<etal/>
</person-group>. (<year>2006a</year>) <article-title>Open study of creatine monohydrate in treatment-resistant posttraumatic stress disorder</article-title>. <source>Journal of Clinical Psychiatry</source> <volume>67</volume>: <fpage>836</fpage>–<lpage>837</lpage>.</citation>
</ref>
<ref id="bibr14-0004867412449303">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Amital</surname><given-names>D</given-names></name>
<name><surname>Vishne</surname><given-names>T</given-names></name>
<name><surname>Rubinow</surname><given-names>A</given-names></name>
<etal/>
</person-group>. (<year>2006b</year>) <article-title>Observed effects of creatine monohydrate in a patient with depression and fibromyalgia</article-title>. <source>American Journal of Psychiatry</source> <volume>163</volume>: <fpage>1840</fpage>–<lpage>1841</lpage>.</citation>
</ref>
<ref id="bibr15-0004867412449303">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Andreassen</surname><given-names>OA</given-names></name>
<name><surname>Dedeoglu</surname><given-names>A</given-names></name>
<name><surname>Ferrante</surname><given-names>RJ</given-names></name>
<etal/>
</person-group>. (<year>2001</year>) <article-title>Creatine increase survival and delays motor symptoms in a transgenic animal model of Huntington’s disease</article-title>. <source>Neurobiology of Disease</source> <volume>8</volume>: <fpage>479</fpage>–<lpage>491</lpage>.</citation>
</ref>
<ref id="bibr16-0004867412449303">
<citation citation-type="journal">
<collab>Anonymous</collab> (<year>1998</year>) <article-title>A randomized, double-blind, placebo-controlled trial of deprenyl and thioctic acid in human immunodeficiency virus-associated cognitive impairment. Dana Consortium on the Therapy of HIV Dementia and Related Cognitive Disorders</article-title>. <source>Neurology</source> <volume>50</volume>: <fpage>645</fpage>–<lpage>651</lpage>.</citation>
</ref>
<ref id="bibr17-0004867412449303">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Arnold</surname><given-names>LE</given-names></name>
<name><surname>Amato</surname><given-names>A</given-names></name>
<name><surname>Bozzolo</surname><given-names>H</given-names></name>
<etal/>
</person-group>. (<year>2007</year>) <article-title>Acetyl-L-carnitine (ALC) in attention-deficit/hyperactivity disorder: A multi-site, placebo-controlled pilot trial</article-title>. <source>Journal of Child and Adolescent Psychopharmacology</source> <volume>17</volume>: <fpage>791</fpage>–<lpage>802</lpage>.</citation>
</ref>
<ref id="bibr18-0004867412449303">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Atkuri</surname><given-names>KR</given-names></name>
<name><surname>Mantovani</surname><given-names>JJ</given-names></name>
<name><surname>Herzenberg</surname><given-names>LA</given-names></name>
<etal/>
</person-group>. (<year>2007</year>) <article-title>N-Acetylcysteine—A safe antidote for cysteine/glutathione deficiency</article-title>. <source>Current Opinion in Pharmacology</source> <volume>7</volume>: <fpage>355</fpage>–<lpage>359</lpage>.</citation>
</ref>
<ref id="bibr19-0004867412449303">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Aureli</surname><given-names>T</given-names></name>
<name><surname>Miccheli</surname><given-names>A</given-names></name>
<name><surname>Ricciolini</surname><given-names>R</given-names></name>
<etal/>
</person-group>. (<year>1990</year>) <article-title>Aging brain: Effect of acetyl-L-carnitine treatment on rat brain energy and phospholipid metabolism. A study by 31P and 1H NMR spectroscopy</article-title>. <source>Brain Research</source> <volume>526</volume>: <fpage>108</fpage>–<lpage>112</lpage>.</citation>
</ref>
<ref id="bibr20-0004867412449303">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Barbiroli</surname><given-names>B</given-names></name>
<name><surname>Montagna</surname><given-names>P</given-names></name>
<name><surname>Martinelli</surname><given-names>P</given-names></name>
<etal/>
</person-group>. (<year>1993</year>) <article-title>Defective brain energy metabolism shown by in vivo 31P MR spectroscopy in 28 patients with mitochondrial cytopathies</article-title>. <source>Journal of Cerebral Blood Flow and Metabolism</source> <volume>13</volume>: <fpage>469</fpage>–<lpage>474</lpage>.</citation>
</ref>
<ref id="bibr21-0004867412449303">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bella</surname><given-names>R</given-names></name>
<name><surname>Biondi</surname><given-names>R</given-names></name>
<name><surname>Raffaele</surname><given-names>R</given-names></name>
<etal/>
</person-group>. (<year>1990</year>) <article-title>Effect of acetyl-L-carnitine on geriatric patients suffering from dysthymic disorders</article-title>. <source>International Journal of Clinical Pharmacology Research</source> <volume>10</volume>: <fpage>355</fpage>–<lpage>360</lpage>.</citation>
</ref>
<ref id="bibr22-0004867412449303">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bender</surname><given-names>A</given-names></name>
<name><surname>Koch</surname><given-names>W</given-names></name>
<name><surname>Elstner</surname><given-names>M</given-names></name>
<etal/>
</person-group>. (<year>2006</year>) <article-title>Creatine supplementation in Parkinson disease: A placebo-controlled randomized pilot trial</article-title>. <source>Neurology</source> <volume>67</volume>: <fpage>1262</fpage>–<lpage>1264</lpage>.</citation>
</ref>
<ref id="bibr23-0004867412449303">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Benes</surname><given-names>FM</given-names></name>
<name><surname>Matzilevich</surname><given-names>D</given-names></name>
<name><surname>Burke</surname><given-names>RE</given-names></name>
<etal/>
</person-group>. (<year>2006</year>) <article-title>The expression of proapoptosis genes is increased in bipolar disorder, but not in schizophrenia</article-title>. <source>Molecular Psychiatry</source> <volume>11</volume>: <fpage>241</fpage>–<lpage>251</lpage>.</citation>
</ref>
<ref id="bibr24-0004867412449303">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Berk</surname><given-names>M</given-names></name>
<name><surname>Copolov</surname><given-names>D</given-names></name>
<name><surname>Dean</surname><given-names>O</given-names></name>
<etal/>
</person-group>. (<year>2008a</year>) <article-title><italic>N</italic>-Acetyl cysteine as a glutathione precursor for schizophrenia—A double-blind, randomized, placebo-controlled trial</article-title>. <source>Biological Psychiatry</source> <volume>64</volume>: <fpage>361</fpage>–<lpage>368</lpage>.</citation>
</ref>
<ref id="bibr25-0004867412449303">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Berk</surname><given-names>M</given-names></name>
<name><surname>Copolov</surname><given-names>DL</given-names></name>
<name><surname>Dean</surname><given-names>O</given-names></name>
<etal/>
</person-group>. (<year>2008b</year>) <article-title><italic>N</italic>-Acetyl cysteine for depressive symptoms in bipolar disorder—A double-blind randomized placebo-controlled trial</article-title>. <source>Biological Psychiatry</source> <volume>64</volume>: <fpage>468</fpage>–<lpage>475</lpage>.</citation>
</ref>
<ref id="bibr26-0004867412449303">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Berlanga</surname><given-names>C</given-names></name>
<name><surname>Ortegasoto</surname><given-names>HA</given-names></name>
<name><surname>Ontiveros</surname><given-names>M</given-names></name>
<etal/>
</person-group>. (<year>1992</year>) <article-title>Efficacy of</article-title> <source>S</source>-adenosyl-L-methionine in speeding the onset of action of imipramine. <source>Psychiatry Research</source> <volume>44</volume>: <fpage>257</fpage>–<lpage>262</lpage>.</citation>
</ref>
<ref id="bibr27-0004867412449303">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bernardi</surname><given-names>P</given-names></name>
<name><surname>Colonna</surname><given-names>R</given-names></name>
<name><surname>Costantini</surname><given-names>P</given-names></name>
<etal/>
</person-group>. (<year>1998</year>) <article-title>The mitochondrial permeability transition</article-title>. <source>Biofactors</source> <volume>8</volume>: <fpage>273</fpage>–<lpage>281</lpage>.</citation>
</ref>
<ref id="bibr28-0004867412449303">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bersani</surname><given-names>G</given-names></name>
<name><surname>Garavini</surname><given-names>A</given-names></name>
</person-group> (<year>2000</year>) <article-title>Melatonin add-on in manic patients with treatment resistant insomnia</article-title>. <source>Progress in Neuro-Psychopharmacology &amp; Biological Psychiatry</source> <volume>24</volume>: <fpage>185</fpage>–<lpage>191</lpage>.</citation>
</ref>
<ref id="bibr29-0004867412449303">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bertolino</surname><given-names>A</given-names></name>
<name><surname>Frye</surname><given-names>M</given-names></name>
<name><surname>Callicott</surname><given-names>JH</given-names></name>
<etal/>
</person-group>. (<year>2003</year>) <article-title>Neuronal pathology in the hippocampal area of patients with bipolar disorder: A study with proton magnetic resonance spectroscopic imaging</article-title>. <source>Biological Psychiatry</source> <volume>53</volume>: <fpage>906</fpage>–<lpage>913</lpage>.</citation>
</ref>
<ref id="bibr30-0004867412449303">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bonavita</surname><given-names>E</given-names></name>
</person-group> (<year>1986</year>) <article-title>Study of the efficacy and tolerability of L-acetylcarnitine therapy in the senile brain</article-title>. <source>International Journal of Clinical Pharmacology, Therapy, and Toxicology</source> <volume>24</volume>: <fpage>511</fpage>–<lpage>516</lpage>.</citation>
</ref>
<ref id="bibr31-0004867412449303">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bottiglieri</surname><given-names>T</given-names></name>
</person-group> (<year>1996</year>) <article-title>Folate, vitamin B-12, and neuropsychiatric disorders</article-title>. <source>Nutrition Reviews</source> <volume>54</volume>: <fpage>382</fpage>–<lpage>390</lpage>.</citation>
</ref>
<ref id="bibr32-0004867412449303">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bottiglieri</surname><given-names>T</given-names></name>
<name><surname>Laundy</surname><given-names>M</given-names></name>
<name><surname>Crellin</surname><given-names>R</given-names></name>
<etal/>
</person-group>. (<year>2000</year>) <article-title>Homocysteine, folate, methylation, and monoamine metabolism in depression</article-title>. <source>Journal of Neurology Neurosurgery and Psychiatry</source> <volume>69</volume>: <fpage>228</fpage>–<lpage>232</lpage>.</citation>
</ref>
<ref id="bibr33-0004867412449303">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Calabrese</surname><given-names>JR</given-names></name>
<name><surname>Guelfi</surname><given-names>JD</given-names></name>
<name><surname>Perdrizet-Chevallier</surname><given-names>C</given-names></name>
</person-group>; <collab>Agomelatine Bipolar Study Group</collab> (<year>2007</year>) <article-title>Agomelatine adjunctive therapy for acute bipolar depression: Preliminary open data</article-title>. <source>Bipolar Disorders</source> <volume>9</volume>: <fpage>628</fpage>–<lpage>635</lpage>.</citation>
</ref>
<ref id="bibr34-0004867412449303">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Cardinali</surname><given-names>DP</given-names></name>
<name><surname>Brusco</surname><given-names>LI</given-names></name>
<name><surname>Liberczuk</surname><given-names>C</given-names></name>
<etal/>
</person-group>. (<year>2002</year>) <article-title>The use of melatonin in Alzheimer’s disease</article-title>. <source>Neuro Endocrinology Letters</source> <volume>23</volume> <supplement>Suppl 1</supplement>: <fpage>20</fpage>–<lpage>23</lpage>.</citation>
</ref>
<ref id="bibr35-0004867412449303">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Carman</surname><given-names>JS</given-names></name>
<name><surname>Post</surname><given-names>RM</given-names></name>
<name><surname>Buswell</surname><given-names>R</given-names></name>
<etal/>
</person-group>. (<year>1976</year>) <article-title>Negative effects of melatonin on depression</article-title>. <source>American Journal of Psychiatry</source> <volume>133</volume>: <fpage>1181</fpage>–<lpage>1186</lpage>.</citation>
</ref>
<ref id="bibr36-0004867412449303">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Carney</surname><given-names>MW</given-names></name>
<name><surname>Chary</surname><given-names>TK</given-names></name>
<name><surname>Bottiglieri</surname><given-names>T</given-names></name>
<etal/>
</person-group>. (<year>1989</year>) <article-title>The switch mechanism and the bipolar/unipolar dichotomy</article-title>. <source>British Journal of Psychiatry</source> <volume>154</volume>: <fpage>48</fpage>–<lpage>51</lpage>.</citation>
</ref>
<ref id="bibr37-0004867412449303">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Cataldo</surname><given-names>AM</given-names></name>
<name><surname>McPhie</surname><given-names>DL</given-names></name>
<name><surname>Lange</surname><given-names>NT</given-names></name>
<etal/>
</person-group>. (<year>2010</year>) <article-title>Abnormalities in mitochondrial structure in cells from patients with bipolar disorder</article-title>. <source>American Journal of Pathology</source> <volume>177</volume>: <fpage>575</fpage>–<lpage>585</lpage>.</citation>
</ref>
<ref id="bibr38-0004867412449303">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Chang</surname><given-names>YYC</given-names></name>
<name><surname>Rapoport</surname><given-names>SI</given-names></name>
<name><surname>Rao</surname><given-names>JS</given-names></name>
</person-group> (<year>2009</year>) <article-title>Chronic administration of mood stabilizers upregulates BDNF and Bcl-2 expression levels in rat frontal cortex</article-title>. <source>Neurochemical Research</source> <volume>34</volume>: <fpage>536</fpage>–<lpage>541</lpage>.</citation>
</ref>
<ref id="bibr39-0004867412449303">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Chen</surname><given-names>G</given-names></name>
<name><surname>Zeng</surname><given-names>WZ</given-names></name>
<name><surname>Yuan</surname><given-names>PX</given-names></name>
<etal/>
</person-group>. (<year>1999</year>) <article-title>The mood-stabilizing agents lithium and valproate robustly increase the levels of the neuroprotective protein bcl-2 in the CNS</article-title>. <source>Journal of Neurochemistry</source> <volume>72</volume>: <fpage>879</fpage>–<lpage>882</lpage>.</citation>
</ref>
<ref id="bibr40-0004867412449303">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Clark</surname><given-names>J</given-names></name>
</person-group> (<year>1998</year>) <article-title><italic>N</italic>-Acetyl aspartate: A marker for neuronal loss or mitochondrial dysfunction</article-title>. <source>Developmental Neuroscience</source> <volume>20</volume>: <fpage>271</fpage>–<lpage>276</lpage>.</citation>
</ref>
<ref id="bibr41-0004867412449303">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Clay</surname><given-names>HB</given-names></name>
<name><surname>Sillivan</surname><given-names>S</given-names></name>
<name><surname>Konradi</surname><given-names>C</given-names></name>
</person-group> (<year>2011</year>) <article-title>Mitochondrial dysfunction and pathology in bipolar disorder and schizophrenia</article-title>. <source>International Journal of Developmental Neuroscience</source> <volume>29</volume>: <fpage>311</fpage>–<lpage>324</lpage>.</citation>
</ref>
<ref id="bibr42-0004867412449303">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Cui</surname><given-names>J</given-names></name>
<name><surname>Shao</surname><given-names>L</given-names></name>
<name><surname>Young</surname><given-names>LT</given-names></name>
<etal/>
</person-group>. (<year>2007</year>) <article-title>Role of glutathione in neuroprotective effects of mood stabilizing drugs lithium and valproate</article-title>. <source>Neuroscience</source> <volume>144</volume>: <fpage>1447</fpage>–<lpage>1453</lpage>.</citation>
</ref>
<ref id="bibr43-0004867412449303">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Cui</surname><given-names>X</given-names></name>
<name><surname>Zuo</surname><given-names>P</given-names></name>
<name><surname>Zhang</surname><given-names>Q</given-names></name>
<etal/>
</person-group>. (<year>2006</year>) <article-title>Chronic systemic <sc>d</sc>-galactose exposure induces memory loss, neurodegeneration, and oxidative damage in mice: Protective effects of R-a-lipoic acid</article-title>. <source>Journal of Neuroscience Research</source> <volume>83</volume>: <fpage>1584</fpage>–<lpage>1590</lpage>.</citation>
</ref>
<ref id="bibr44-0004867412449303">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Culmsee</surname><given-names>C</given-names></name>
<name><surname>Mattson</surname><given-names>M</given-names></name>
</person-group> (<year>2005</year>) <article-title>p53 in neuronal apoptosis</article-title>. <source>Biochemical and Biophysical Research Communications</source> <volume>331</volume>: <fpage>761</fpage>–<lpage>777</lpage>.</citation>
</ref>
<ref id="bibr45-0004867412449303">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Dager</surname><given-names>SR</given-names></name>
<name><surname>Friedman</surname><given-names>SD</given-names></name>
<name><surname>Parow</surname><given-names>A</given-names></name>
<etal/>
</person-group>. (<year>2004</year>) <article-title>Brain metabolic alterations in medication-free patients with bipolar disorder</article-title>. <source>Archives of General Psychiatry</source> <volume>61</volume>: <fpage>450</fpage>–<lpage>458</lpage>.</citation>
</ref>
<ref id="bibr46-0004867412449303">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Dechent</surname><given-names>P</given-names></name>
<name><surname>Pouwels</surname><given-names>PJ</given-names></name>
<name><surname>Wilken</surname><given-names>B</given-names></name>
<etal/>
</person-group>. (<year>1999</year>) <article-title>Increase of total creatine in human brain after oral supplementation of creatine-monohydrate</article-title>. <source>American Journal of Physiology</source> <volume>277</volume>: <fpage>R698</fpage>–<lpage>R704</lpage>.</citation>
</ref>
<ref id="bibr47-0004867412449303">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>De Grandis</surname><given-names>D</given-names></name>
<name><surname>Minardi</surname><given-names>C</given-names></name>
</person-group> (<year>2002</year>) <article-title>Acetyl-L-carnitine (levacecarnine) in the treatment of diabetic neuropathy. A long-term, randomised, double-blind, placebo-controlled study</article-title>. <source>Drugs in R &amp; D</source> <volume>3</volume>: <fpage>223</fpage>–<lpage>231</lpage>.</citation>
</ref>
<ref id="bibr48-0004867412449303">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Deicken</surname><given-names>R</given-names></name>
<name><surname>Pegues</surname><given-names>M</given-names></name>
<name><surname>Anzalone</surname><given-names>S</given-names></name>
<etal/>
</person-group>. (<year>2003</year>). <article-title>Lower concentration of hippocampal</article-title> <source>N</source>-acetylaspartate in familial bipolar I disorder. <source>American Journal of Psychiatry</source> <volume>160</volume>: <fpage>873</fpage>–<lpage>882</lpage>.</citation>
</ref>
<ref id="bibr49-0004867412449303">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Eleff</surname><given-names>S</given-names></name>
<name><surname>Barker</surname><given-names>P</given-names></name>
<name><surname>Blackband</surname><given-names>S</given-names></name>
<etal/>
</person-group>. (<year>1990</year>) <article-title>Phosphorus magnetic resonance spectroscopy of patients with mitochondrial cytopathies demonstrates decreased levels of brain phosphocreatine</article-title>. <source>Annals of Neurology</source> <volume>27</volume>: <fpage>626</fpage>–<lpage>630</lpage>.</citation>
</ref>
<ref id="bibr50-0004867412449303">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Elmslie</surname><given-names>JL</given-names></name>
<name><surname>Porter</surname><given-names>RJ</given-names></name>
<name><surname>Joyce</surname><given-names>PR</given-names></name>
<etal/>
</person-group>. (<year>2006</year>) <article-title>Carnitine does not improve weight loss outcomes in valproate-treated bipolar patients consuming an energy-restricted, low-fat diet</article-title>. <source>Bipolar Disorders</source> <volume>8</volume>: <fpage>503</fpage>–<lpage>507</lpage>.</citation>
</ref>
<ref id="bibr51-0004867412449303">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Erecinska</surname><given-names>M</given-names></name>
<name><surname>Silver</surname><given-names>IA</given-names></name>
</person-group> (<year>1989</year>) <article-title>ATP and brain function</article-title>. <source>Journal of Cerebral Blood Flow and Metabolism</source> <volume>9</volume>: <fpage>2</fpage>–<lpage>19</lpage>.</citation>
</ref>
<ref id="bibr52-0004867412449303">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Estrada</surname><given-names>DE</given-names></name>
<name><surname>Ewart</surname><given-names>HS</given-names></name>
<name><surname>Tsakiridis</surname><given-names>T</given-names></name>
<etal/>
</person-group>. (<year>1996</year>) <article-title>Stimulation of glucose uptake by the natural coenzyme alpha-lipoic acid/thioctic acid: Participation of elements of the insulin signaling pathway</article-title>. <source>Diabetes</source> <volume>45</volume>: <fpage>1798</fpage>–<lpage>1804</lpage>.</citation>
</ref>
<ref id="bibr53-0004867412449303">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Feigin</surname><given-names>A</given-names></name>
<name><surname>Kieburtz</surname><given-names>K</given-names></name>
<name><surname>Como</surname><given-names>P</given-names></name>
<etal/>
</person-group>. (<year>1996</year>) <article-title>Assessment of coenzyme Q10 tolerability in Huntington’s disease</article-title>. <source>Movement Disorders</source> <volume>11</volume>: <fpage>321</fpage>–<lpage>323</lpage>.</citation>
</ref>
<ref id="bibr54-0004867412449303">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Femiano</surname><given-names>F</given-names></name>
<name><surname>Scully</surname><given-names>C</given-names></name>
</person-group> (<year>2002</year>) <article-title>Burning mouth syndrome (BMS): Double blind controlled study of alpha-lipoic acid (thioctic acid) therapy</article-title>. <source>Journal of Oral Pathology &amp; Medicine</source> <volume>31</volume>: <fpage>267</fpage>–<lpage>269</lpage>.</citation>
</ref>
<ref id="bibr55-0004867412449303">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ferreira</surname><given-names>MAR</given-names></name>
<name><surname>O’Donovan</surname><given-names>MC</given-names></name>
<name><surname>Meng</surname><given-names>YA</given-names></name>
<etal/>
</person-group>. (<year>2008</year>) <article-title>Collaborative genome-wide association analysis supports a role for ANK3 and CACNA1C in bipolar disorder</article-title>. <source>Nature Genetics</source> <volume>40</volume>: <fpage>1056</fpage>–<lpage>1058</lpage>.</citation>
</ref>
<ref id="bibr56-0004867412449303">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Frey</surname><given-names>BN</given-names></name>
<name><surname>Stanley</surname><given-names>JA</given-names></name>
<name><surname>Nery</surname><given-names>FG</given-names></name>
<etal/>
</person-group>. (<year>2007a</year>) <article-title>Abnormal cellular energy and phospholipid metabolism in the left dorsolateral prefrontal cortex of medication-free individuals with bipolar disorder: An in vivo 1H MRS study</article-title>. <source>Bipolar Disorders</source> <volume>9</volume>: <fpage>119</fpage>–<lpage>127</lpage>.</citation>
</ref>
<ref id="bibr57-0004867412449303">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Frey</surname><given-names>BN</given-names></name>
<name><surname>Walss-Bass</surname><given-names>C</given-names></name>
<name><surname>Stanley</surname><given-names>JA</given-names></name>
<etal/>
</person-group>. (<year>2007b</year>) <article-title>Brain-derived neurotrophic factor val66met polymorphism affects prefrontal energy metabolism in bipolar disorder</article-title>. <source>Neuroreport</source> <volume>18</volume>: <fpage>1567</fpage>–<lpage>1570</lpage>.</citation>
</ref>
<ref id="bibr58-0004867412449303">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Fulgente</surname><given-names>T</given-names></name>
<name><surname>Onofrj</surname><given-names>M</given-names></name>
<name><surname>Del Re</surname><given-names>ML</given-names></name>
<etal/>
</person-group>. (<year>1990</year>) <article-title>Laevo-acetylcarnitine (Nicetile) treatment of senile depression</article-title>. <source>Clinical Trials Journal</source> <volume>27</volume>: <fpage>155</fpage>–<lpage>163</lpage>.</citation>
</ref>
<ref id="bibr59-0004867412449303">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Garcia</surname><given-names>JJ</given-names></name>
<name><surname>Reiter</surname><given-names>RJ</given-names></name>
<name><surname>Guerrero</surname><given-names>JM</given-names></name>
<etal/>
</person-group>. (<year>1997</year>) <article-title>Melatonin prevents changes in microsomal membrane fluidity during induced lipid peroxidation</article-title>. <source>FEBS Letters</source> <volume>408</volume>: <fpage>297</fpage>–<lpage>300</lpage>.</citation>
</ref>
<ref id="bibr60-0004867412449303">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Garzya</surname><given-names>G</given-names></name>
<name><surname>Corallo</surname><given-names>D</given-names></name>
<name><surname>Fiore</surname><given-names>A</given-names></name>
<etal/>
</person-group>. (<year>1990</year>) <article-title>Evaluation of the effects of L-acetylcarnitine on senile patients suffering from depression</article-title>. <source>Drugs Under Experimental and Clinical Research</source> <volume>16</volume>: <fpage>101</fpage>–<lpage>106</lpage>.</citation>
</ref>
<ref id="bibr61-0004867412449303">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Gecele</surname><given-names>M</given-names></name>
<name><surname>Francesetti</surname><given-names>G</given-names></name>
<name><surname>Meluzzi</surname><given-names>A</given-names></name>
</person-group> (<year>1991</year>) <article-title>Acetyl-L-carnitine in aged subjects with major depression: Clinical efficacy and effects on the circadian rhythym of cortisol</article-title>. <source>Dementia</source> <volume>2</volume>: <fpage>333</fpage>–<lpage>337</lpage>.</citation>
</ref>
<ref id="bibr62-0004867412449303">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ghaemi</surname><given-names>SN</given-names></name>
<name><surname>Hsu</surname><given-names>DJ</given-names></name>
<name><surname>Thase</surname><given-names>ME</given-names></name>
<etal/>
</person-group>. (<year>2006</year>) <article-title>Pharmacological treatment patterns at study entry for the first 500 STEP-BD participants</article-title>. <source>Psychiatric Services</source> <volume>57</volume>: <fpage>660</fpage>–<lpage>665</lpage>.</citation>
</ref>
<ref id="bibr63-0004867412449303">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Grant</surname><given-names>JE</given-names></name>
<name><surname>Kim</surname><given-names>SW</given-names></name>
<name><surname>Odlaug</surname><given-names>BL</given-names></name>
</person-group> (<year>2007</year>) <article-title><italic>N</italic>-Acetyl cysteine, a glutamate-modulating agent, in the treatment of pathological gambling: A pilot study</article-title>. <source>Biological Psychiatry</source> <volume>62</volume>: <fpage>652</fpage>–<lpage>657</lpage>.</citation>
</ref>
<ref id="bibr64-0004867412449303">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Groeneveld</surname><given-names>GJ</given-names></name>
<name><surname>Veldink</surname><given-names>JH</given-names></name>
<name><surname>van der Tweel</surname><given-names>I</given-names></name>
<etal/>
</person-group>. (<year>2003</year>) <article-title>A randomized sequential trial of creatine in amyotrophic lateral sclerosis</article-title>. <source>Annals of Neurology</source> <volume>53</volume>: <fpage>437</fpage>–<lpage>445</lpage>.</citation>
</ref>
<ref id="bibr65-0004867412449303">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hagen</surname><given-names>T</given-names></name>
<name><surname>Liu</surname><given-names>J</given-names></name>
<name><surname>Lykkesfeldt</surname><given-names>J</given-names></name>
<etal/>
</person-group>. (<year>2002a</year>) <article-title>Feeding acetyl-L-carnitine and lipoic acid to old rats significantly improves metabolic function while decreasing oxidative stress</article-title>. <source>Proceedings of the National Academy of Sciences of the United States of America</source> <volume>99</volume>: <fpage>1870</fpage>–<lpage>1875</lpage>.</citation>
</ref>
<ref id="bibr66-0004867412449303">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hagen</surname><given-names>TM</given-names></name>
<name><surname>Ingersoll</surname><given-names>RT</given-names></name>
<name><surname>Lykkesfeldt</surname><given-names>J</given-names></name>
<etal/>
</person-group>. (<year>1999</year>) <article-title>(R)-Alpha-lipoic acid-supplemented old rats have improved mitochondrial function, decreased oxidative damage, and increased metabolic rate</article-title>. <source>FASEB Journal</source> <volume>13</volume>: <fpage>411</fpage>–<lpage>418</lpage>.</citation>
</ref>
<ref id="bibr67-0004867412449303">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hagen</surname><given-names>TM</given-names></name>
<name><surname>Moreau</surname><given-names>R</given-names></name>
<name><surname>Suh</surname><given-names>JH</given-names></name>
<etal/>
</person-group>. (<year>2002b</year>) <article-title>Mitochondrial decay in the aging rat heart</article-title>. <source>Annals of the New York Academy of Sciences</source> <volume>959</volume>: <fpage>491</fpage>–<lpage>507</lpage>.</citation>
</ref>
<ref id="bibr68-0004867412449303">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hager</surname><given-names>K</given-names></name>
<name><surname>Kenklies</surname><given-names>M</given-names></name>
<name><surname>McAfoose</surname><given-names>J</given-names></name>
<etal/>
</person-group>. (<year>2007</year>) <article-title>Alpha-lipoic acid as a new treatment option for Alzheimer’s disease—A 48 months follow-up analysis</article-title>. <source>Journal of Neural Transmission</source>. <supplement>Supplement</supplement>: <fpage>189</fpage>–<lpage>193</lpage>.</citation>
</ref>
<ref id="bibr69-0004867412449303">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hahm</surname><given-names>JR</given-names></name>
<name><surname>Kim</surname><given-names>BJ</given-names></name>
<name><surname>Kim</surname><given-names>KW</given-names></name>
</person-group> (<year>2004</year>) <article-title>Clinical experience with thioctacid (thioctic acid) in the treatment of distal symmetric polyneuropathy in Korean diabetic patients</article-title>. <source>Journal of Diabetes and its Complications</source> <volume>18</volume>: <fpage>79</fpage>–<lpage>85</lpage>.</citation>
</ref>
<ref id="bibr70-0004867412449303">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hamakawa</surname><given-names>H</given-names></name>
<name><surname>Kato</surname><given-names>T</given-names></name>
<name><surname>Murashita</surname><given-names>J</given-names></name>
<etal/>
</person-group>. (<year>1998</year>) <article-title>Quantitative proton magnetic resonance spectroscopy of the basal ganglia in patients with affective disorders</article-title>. <source>European Archives of Psychiatry and Clinical Neuroscience</source> <volume>248</volume>: <fpage>53</fpage>–<lpage>58</lpage>.</citation>
</ref>
<ref id="bibr71-0004867412449303">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hamakawa</surname><given-names>H</given-names></name>
<name><surname>Murashita</surname><given-names>J</given-names></name>
<name><surname>Yamada</surname><given-names>N</given-names></name>
<etal/>
</person-group>. (<year>2004</year>) <article-title>Reduced intracellular pH in the basal ganglia and whole brain measured by P-MRS in bipolar disorder</article-title>. <source>Psychiatry Clinical Neuroscience</source> <volume>58</volume>: <fpage>53</fpage>–<lpage>59</lpage>.</citation>
</ref>
<ref id="bibr72-0004867412449303">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hao</surname><given-names>Y</given-names></name>
<name><surname>Basile</surname><given-names>AS</given-names></name>
<name><surname>Chen</surname><given-names>G</given-names></name>
<etal/>
</person-group>. (<year>2004</year>) <article-title>Glutamate-induced over-expression of GAD is down-regulated by acetyl-L-carnitine in rat islet cells</article-title>. <source>Endocrine Research</source> <volume>30</volume>: <fpage>107</fpage>–<lpage>116</lpage>.</citation>
</ref>
<ref id="bibr73-0004867412449303">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hart</surname><given-names>AM</given-names></name>
<name><surname>Wilson</surname><given-names>AD</given-names></name>
<name><surname>Montovani</surname><given-names>C</given-names></name>
<etal/>
</person-group>. (<year>2004</year>) <article-title>Acetyl-L-carnitine: A pathogenesis based treatment for HIV-associated antiretroviral toxic neuropathy</article-title>. <source>AIDS</source> <volume>18</volume>: <fpage>1549</fpage>–<lpage>1560</lpage>.</citation>
</ref>
<ref id="bibr74-0004867412449303">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hershey</surname><given-names>AD</given-names></name>
<name><surname>Powers</surname><given-names>SW</given-names></name>
<name><surname>Vockell</surname><given-names>ALB</given-names></name>
<etal/>
</person-group>. (<year>2007</year>) <article-title>Coenzyme Q10 deficiency and response to supplementation in pediatric and adolescent migraine</article-title>. <source>Headache</source> <volume>47</volume>: <fpage>73</fpage>–<lpage>80</lpage>.</citation>
</ref>
<ref id="bibr75-0004867412449303">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hidaka</surname><given-names>T</given-names></name>
<name><surname>Fujii</surname><given-names>K</given-names></name>
<name><surname>Funahashi</surname><given-names>I</given-names></name>
<etal/>
</person-group>. (<year>2008</year>) <article-title>Safety assessment of coenzyme Q_10 (CoQ_10)</article-title>. <source>Biofactors</source> <volume>32</volume>: <fpage>199</fpage>–<lpage>208</lpage>.</citation>
</ref>
<ref id="bibr76-0004867412449303">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hoppel</surname><given-names>C</given-names></name>
</person-group> (<year>2003</year>) <article-title>The role of carnitine in normal and altered fatty acid metabolism</article-title>. <source>American Journal of Kidney Diseases</source> <volume>41</volume>: <fpage>S4</fpage>–<lpage>S12</lpage>.</citation>
</ref>
<ref id="bibr77-0004867412449303">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Jacob</surname><given-names>S</given-names></name>
<name><surname>Ruus</surname><given-names>P</given-names></name>
<name><surname>Hermann</surname><given-names>R</given-names></name>
<etal/>
</person-group>. (<year>1999</year>) <article-title>Oral administration of RAC-alpha-lipoic acid modulates insulin sensitivity in patients with type-2 diabetes mellitus: A placebo-controlled pilot trial</article-title>. <source>Journal of Free Radicals in Biology &amp; Medicine</source> <volume>27</volume>: <fpage>309</fpage>–<lpage>314</lpage>.</citation>
</ref>
<ref id="bibr78-0004867412449303">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Judd</surname><given-names>LL</given-names></name>
<name><surname>Schettler</surname><given-names>PJ</given-names></name>
<name><surname>Akiskal</surname><given-names>HS</given-names></name>
<etal/>
</person-group>. (<year>2008</year>) <article-title>Residual symptom recovery from major affective episodes in bipolar disorders and rapid episode relapse/recurrence</article-title>. <source>Archives of General Psychiatry</source> <volume>65</volume>: <fpage>386</fpage>–<lpage>394</lpage>.</citation>
</ref>
<ref id="bibr79-0004867412449303">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Juhn</surname><given-names>MS</given-names></name>
<name><surname>Tarnopolsky</surname><given-names>M</given-names></name>
</person-group> (<year>1998</year>) <article-title>Oral creatine supplementation and athletic performance: A critical review</article-title>. <source>Clinical Journal of Sport Medicine</source> <volume>8</volume>: <fpage>286</fpage>–<lpage>297</lpage>.</citation>
</ref>
<ref id="bibr80-0004867412449303">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kapczinski</surname><given-names>F</given-names></name>
<name><surname>Vieta</surname><given-names>E</given-names></name>
<name><surname>Andreazza</surname><given-names>AC</given-names></name>
<etal/>
</person-group>. (<year>2008</year>) <article-title>Allostatic load in bipolar disorder: Implications for pathophysiology and treatment</article-title>. <source>Neuroscience and Biobehavioral Reviews</source> <volume>32</volume>: <fpage>675</fpage>–<lpage>692</lpage>.</citation>
</ref>
<ref id="bibr81-0004867412449303">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kaptsan</surname><given-names>A</given-names></name>
<name><surname>Odessky</surname><given-names>A</given-names></name>
<name><surname>Osher</surname><given-names>Y</given-names></name>
<etal/>
</person-group>. (<year>2007</year>) <article-title>Lack of efficacy of 5 grams daily of creatine in schizophrenia: A randomized, double-blind, placebo-controlled trial</article-title>. <source>Journal of Clinical Psychiatry</source> <volume>68</volume>: <fpage>881</fpage>–<lpage>884</lpage>.</citation>
</ref>
<ref id="bibr82-0004867412449303">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kato</surname><given-names>T</given-names></name>
</person-group> (<year>2008</year>) <article-title>Role of mitochondrial DNA in calcium signaling abnormality in bipolar disorder</article-title>. <source>Cell Calcium</source> <volume>44</volume>: <fpage>92</fpage>–<lpage>102</lpage>.</citation>
</ref>
<ref id="bibr83-0004867412449303">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kato</surname><given-names>T</given-names></name>
<name><surname>Murashita</surname><given-names>J</given-names></name>
<name><surname>Kamiya</surname><given-names>A</given-names></name>
<etal/>
</person-group>. (<year>1998</year>) <article-title>Decreased brain intracellular pH measured by P-31-MRS in bipolar disorder: A confirmation in drug-free patients and correlation with white matter hyperintensity</article-title>. <source>European Archives of Psychiatry and Clinical Neuroscience</source> <volume>248</volume>: <fpage>301</fpage>–<lpage>306</lpage>.</citation>
</ref>
<ref id="bibr84-0004867412449303">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kato</surname><given-names>T</given-names></name>
<name><surname>Shioiri</surname><given-names>T</given-names></name>
<name><surname>Murashita</surname><given-names>J</given-names></name>
<etal/>
</person-group>. (<year>1995</year>) <article-title>Lateralized abnormality of high energy phosphate metabolism in the frontal lobes of patients with bipolar disorder detected by phase-encoded 31P-MRS</article-title>. <source>Psychological Medicine</source> <volume>25</volume>: <fpage>557</fpage>–<lpage>566</lpage>.</citation>
</ref>
<ref id="bibr85-0004867412449303">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kato</surname><given-names>T</given-names></name>
<name><surname>Takahashi</surname><given-names>S</given-names></name>
<name><surname>Shioiri</surname><given-names>T</given-names></name>
<etal/>
</person-group>. (<year>1994</year>) <article-title>Reduction of brain phosphocreatine in bipolar II disorder detected by phosphorus-31 magnetic resonance spectroscopy</article-title>. <source>Journal of Affective Disorders</source> <volume>31</volume>: <fpage>125</fpage>–<lpage>133</lpage>.</citation>
</ref>
<ref id="bibr86-0004867412449303">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kazuno</surname><given-names>A</given-names></name>
<name><surname>Munakata</surname><given-names>K</given-names></name>
<name><surname>Kato</surname><given-names>N</given-names></name>
<etal/>
</person-group>. (<year>2008</year>) <article-title>Mitochondrial DNA-dependent effects of valproate on mitochondrial calcium levels in transmitochondrial cybrids</article-title>. <source>International Journal of Neuropsychopharmacology</source> <volume>11</volume>: <fpage>71</fpage>–<lpage>78</lpage>.</citation>
</ref>
<ref id="bibr87-0004867412449303">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Klivenyi</surname><given-names>P</given-names></name>
<name><surname>Ferrante</surname><given-names>RJ</given-names></name>
<name><surname>Matthews</surname><given-names>RT</given-names></name>
<etal/>
</person-group>. (<year>1999</year>) <article-title>Neuroprotective effects of creatine in a transgenic animal model of amyotrophic lateral sclerosis</article-title>. <source>Nature Medicine</source> <volume>5</volume>: <fpage>347</fpage>–<lpage>350</lpage>.</citation>
</ref>
<ref id="bibr88-0004867412449303">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Konradi</surname><given-names>C</given-names></name>
<name><surname>Eaton</surname><given-names>M</given-names></name>
<name><surname>MacDonald</surname><given-names>ML</given-names></name>
<etal/>
</person-group>. (<year>2004</year>) <article-title>Molecular evidence for mitochondrial dysfunction in bipolar disorder</article-title>. <source>Archives of General Psychiatry</source> <volume>61</volume>: <fpage>301</fpage>–<lpage>308</lpage>.</citation>
</ref>
<ref id="bibr89-0004867412449303">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Korkmaz</surname><given-names>A</given-names></name>
<name><surname>Reiter</surname><given-names>RJ</given-names></name>
<name><surname>Topal</surname><given-names>T</given-names></name>
<etal/>
</person-group>. (<year>2009</year>) <article-title>Melatonin: An established antioxidant worthy of use in clinical trials</article-title>. <source>Molecular Medicine</source> <volume>15</volume>: <fpage>43</fpage>–<lpage>50</lpage>.</citation>
</ref>
<ref id="bibr90-0004867412449303">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kwong</surname><given-names>LK</given-names></name>
<name><surname>Kamzalov</surname><given-names>S</given-names></name>
<name><surname>Rebrin</surname><given-names>I</given-names></name>
<etal/>
</person-group>. (<year>2002</year>) <article-title>Effects of coenzyme Q10 administration on its tissue concentrations, mitochondrial oxidant generation, and oxidative stress in the rat</article-title>. <source>Free Radical Biology and Medicine</source> <volume>33</volume>: <fpage>627</fpage>–<lpage>638</lpage>.</citation>
</ref>
<ref id="bibr91-0004867412449303">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lafer</surname><given-names>B</given-names></name>
<name><surname>Renshaw</surname><given-names>PF</given-names></name>
<name><surname>Sachs</surname><given-names>G</given-names></name>
<etal/>
</person-group>. (<year>1994</year>) <article-title>Proton MRS of the basal ganglia in bipolar disorder</article-title>. <source>Biological Psychiatry</source> <volume>35</volume>: <fpage>685</fpage>.</citation>
</ref>
<ref id="bibr92-0004867412449303">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lahiri</surname><given-names>DK</given-names></name>
<name><surname>Chen</surname><given-names>D</given-names></name>
<name><surname>Ge</surname><given-names>YW</given-names></name>
<etal/>
</person-group>. (<year>2004</year>) <article-title>Dietary supplementation with melatonin reduces levels of amyloid beta-peptides in the murine cerebral cortex</article-title>. <source>Journal of Pineal Research</source> <volume>36</volume>: <fpage>224</fpage>–<lpage>231</lpage>.</citation>
</ref>
<ref id="bibr93-0004867412449303">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lawler</surname><given-names>JM</given-names></name>
<name><surname>Barnes</surname><given-names>WS</given-names></name>
<name><surname>Wu</surname><given-names>G</given-names></name>
<etal/>
</person-group>. (<year>2002</year>) <article-title>Direct antioxidant properties of creatine</article-title>. <source>Biochemical and Biophysical Research Communications</source> <volume>290</volume>: <fpage>47</fpage>–<lpage>52</lpage>.</citation>
</ref>
<ref id="bibr94-0004867412449303">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Leibenluft</surname><given-names>E</given-names></name>
<name><surname>Feldman-Naim</surname><given-names>S</given-names></name>
<name><surname>Turner</surname><given-names>EH</given-names></name>
<etal/>
</person-group>. (<year>1997</year>) <article-title>Effects of exogenous melatonin administration and withdrawal in five patients with rapid-cycling bipolar disorder</article-title>. <source>Journal of Clinical Psychiatry</source> <volume>58</volume>: <fpage>383</fpage>–<lpage>388</lpage>.</citation>
</ref>
<ref id="bibr95-0004867412449303">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Leon</surname><given-names>J</given-names></name>
<name><surname>Acuña-Castroviejo</surname><given-names>D</given-names></name>
<name><surname>Escames</surname><given-names>G</given-names></name>
<etal/>
</person-group>. (<year>2005</year>) <article-title>Melatonin mitigates mitochondrial malfunction</article-title>. <source>Journal of Pineal Research</source> <volume>38</volume>: <fpage>1</fpage>–<lpage>9</lpage>.</citation>
</ref>
<ref id="bibr96-0004867412449303">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Leon</surname><given-names>J</given-names></name>
<name><surname>Acuña-Castroviejo</surname><given-names>D</given-names></name>
<name><surname>Sainz</surname><given-names>RM</given-names></name>
<etal/>
</person-group>. (<year>2004</year>) <article-title>Melatonin and mitochondrial function</article-title>. <source>Life Sciences</source> <volume>75</volume>: <fpage>765</fpage>–<lpage>790</lpage>.</citation>
</ref>
<ref id="bibr97-0004867412449303">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Leppamaki</surname><given-names>S</given-names></name>
<name><surname>Partonen</surname><given-names>T</given-names></name>
<name><surname>Vakkuri</surname><given-names>O</given-names></name>
<etal/>
</person-group>. (<year>2003</year>) <article-title>Effect of controlled-release melatonin on sleep quality, mood, and quality of life in subjects with seasonal or weather-associated changes in mood and behaviour</article-title>. <source>European Neuropsychopharmacology</source> <volume>13</volume>: <fpage>137</fpage>–<lpage>145</lpage>.</citation>
</ref>
<ref id="bibr98-0004867412449303">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lewy</surname><given-names>AJ</given-names></name>
<name><surname>Bauer</surname><given-names>VK</given-names></name>
<name><surname>Cutler</surname><given-names>NL</given-names></name>
<etal/>
</person-group>. (<year>1998</year>) <article-title>Melatonin treatment of winter depression: A pilot study</article-title>. <source>Psychiatry Research</source> <volume>77</volume>: <fpage>57</fpage>–<lpage>61</lpage>.</citation>
</ref>
<ref id="bibr99-0004867412449303">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lipinski</surname><given-names>JF</given-names></name>
<name><surname>Cohen</surname><given-names>BM</given-names></name>
<name><surname>Frankenburg</surname><given-names>F</given-names></name>
<etal/>
</person-group>. (<year>1984</year>) <article-title>Open trial of <italic>S</italic>-adenosylmethionine for treatment of depression</article-title>. <source>American Journal of Psychiatry</source> <volume>141</volume>: <fpage>448</fpage>–<lpage>450</lpage>.</citation>
</ref>
<ref id="bibr100-0004867412449303">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Liu</surname><given-names>J</given-names></name>
</person-group> (<year>2008</year>) <article-title>The effects and mechanisms of mitochondrial nutrient alpha-lipoic acid on improving age-associated mitochondrial and cognitive dysfunction: An overview</article-title>. <source>Neurochemical Research</source> <volume>33</volume>: <fpage>194</fpage>–<lpage>203</lpage>.</citation>
</ref>
<ref id="bibr101-0004867412449303">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Liu</surname><given-names>J</given-names></name>
<name><surname>Atamna</surname><given-names>H</given-names></name>
<name><surname>Kuratsune</surname><given-names>H</given-names></name>
<etal/>
</person-group>. (<year>2002a</year>) <article-title>Delaying brain mitochondrial decay and aging with mitochondrial antioxidants and metabolites</article-title>. <source>Annals of the New York Academy of Sciences</source> <volume>959</volume>: <fpage>133</fpage>–<lpage>166</lpage>.</citation>
</ref>
<ref id="bibr102-0004867412449303">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Liu</surname><given-names>J</given-names></name>
<name><surname>Head</surname><given-names>E</given-names></name>
<name><surname>Gharib</surname><given-names>AM</given-names></name>
<etal/>
</person-group>. (<year>2002b</year>) <article-title>Memory loss in old rats is associated with brain mitochondrial decay and RNA/DNA oxidation: Partial reversal by feeding acetyl-L-carnitine and/or R-alpha-lipoic acid</article-title>. <source>Proceedings of the National Academy of Sciences of the United States of America</source> <volume>99</volume>: <fpage>2356</fpage>–<lpage>2361</lpage>.</citation>
</ref>
<ref id="bibr103-0004867412449303">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lopez-Burillo</surname><given-names>S</given-names></name>
<name><surname>Tan</surname><given-names>DX</given-names></name>
<name><surname>Mayo</surname><given-names>JC</given-names></name>
<etal/>
</person-group>. (<year>2003</year>) <article-title>Melatonin, xanthurenic acid, resveratrol, EGCG, vitamin C and alpha-lipoic acid differentially reduce oxidative DNA damage induced by Fenton reagents: A study of their individual and synergistic actions</article-title>. <source>Journal of Pineal Research</source> <volume>34</volume>: <fpage>269</fpage>–<lpage>277</lpage>.</citation>
</ref>
<ref id="bibr104-0004867412449303">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lyoo</surname><given-names>IK</given-names></name>
<name><surname>Kong</surname><given-names>SW</given-names></name>
<name><surname>Sung</surname><given-names>SM</given-names></name>
<etal/>
</person-group>. (<year>2003</year>) <article-title>Multinuclear magnetic resonance spectroscopy of high-energy phosphate metabolites in human brain following oral supplementation of creatine-monohydrate</article-title>. <source>Psychiatry Research</source> <volume>123</volume>: <fpage>87</fpage>–<lpage>100</lpage>.</citation>
</ref>
<ref id="bibr105-0004867412449303">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Magis</surname><given-names>D</given-names></name>
<name><surname>Ambrosini</surname><given-names>A</given-names></name>
<name><surname>Sandor</surname><given-names>P</given-names></name>
<etal/>
</person-group>. (<year>2007</year>) <article-title>A randomized double-blind placebo-controlled trial of thioctic acid in migraine prophylaxis</article-title>. <source>Headache</source> <volume>47</volume>: <fpage>52</fpage>–<lpage>57</lpage>.</citation>
</ref>
<ref id="bibr106-0004867412449303">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Malaguarnera</surname><given-names>M</given-names></name>
<name><surname>Gargante</surname><given-names>MP</given-names></name>
<name><surname>Cristaldi</surname><given-names>E</given-names></name>
<etal/>
</person-group>. (<year>2008</year>) <article-title>Acetyl-L-carnitine treatment in minimal hepatic encephalopathy</article-title>. <source>Digestive Diseases and Sciences</source> <volume>53</volume>: <fpage>3018</fpage>–<lpage>3025</lpage>.</citation>
</ref>
<ref id="bibr107-0004867412449303">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Malaguarnera</surname><given-names>M</given-names></name>
<name><surname>Pistone</surname><given-names>G</given-names></name>
<name><surname>Astuto</surname><given-names>M</given-names></name>
<etal/>
</person-group>. (<year>2006</year>) <article-title>Effects of L-acetylcarnitine on cirrhotic patients with hepatic coma: Randomized double-blind, placebo-controlled trial</article-title>. <source>Digestive Diseases and Sciences</source> <volume>51</volume>: <fpage>2242</fpage>–<lpage>2247</lpage>.</citation>
</ref>
<ref id="bibr108-0004867412449303">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Manji</surname><given-names>H</given-names></name>
<name><surname>Moore</surname><given-names>G</given-names></name>
<name><surname>Chen</surname><given-names>G</given-names></name>
</person-group> (<year>2000</year>) <article-title>Clinical and preclinical evidence for the neurotrophic effects of mood stabilizers: Implications for the pathophysiology and treatment of manic-depressive illness</article-title>. <source>Biological Psychiatry</source> <volume>48</volume>: <fpage>740</fpage>–<lpage>754</lpage>.</citation>
</ref>
<ref id="bibr109-0004867412449303">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Marshall</surname><given-names>AW</given-names></name>
<name><surname>Graul</surname><given-names>RS</given-names></name>
<name><surname>Morgan</surname><given-names>MY</given-names></name>
<etal/>
</person-group>. (<year>1982</year>) <article-title>Treatment of alcohol-related liver disease with thioctic acid: A six month randomised double-blind trial</article-title>. <source>Gut</source> <volume>23</volume>: <fpage>1088</fpage>–<lpage>1093</lpage>.</citation>
</ref>
<ref id="bibr110-0004867412449303">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Mathew</surname><given-names>SJ</given-names></name>
<name><surname>Manji</surname><given-names>HK</given-names></name>
<name><surname>Charney</surname><given-names>DS</given-names></name>
</person-group> (<year>2008</year>) <article-title>Novel drugs and therapeutic targets for severe mood disorders</article-title>. <source>Neuropsychopharmacology</source> <volume>33</volume>: <fpage>2080</fpage>–<lpage>2092</lpage>.</citation>
</ref>
<ref id="bibr111-0004867412449303">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Mattson</surname><given-names>M</given-names></name>
<name><surname>Liu</surname><given-names>D</given-names></name>
</person-group> (<year>2003</year>) <article-title>Mitochondrial potassium channels and uncoupling proteins in synaptic plasticity and neuronal cell death</article-title>. <source>Biochemical and Biophysical Research Communications</source> <volume>304</volume>: <fpage>539</fpage>–<lpage>549</lpage>.</citation>
</ref>
<ref id="bibr112-0004867412449303">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Mayer</surname><given-names>M</given-names></name>
<name><surname>Noble</surname><given-names>M</given-names></name>
</person-group> (<year>1994</year>) <article-title><italic>N</italic>-acetyl-L-cysteine is a pluripotent protector against cell death and enhancer of trophic factor-mediated cell survival in vitro</article-title>. <source>Proceedings of the National Academy of Sciences of the United States of America</source> <volume>91</volume>: <fpage>7496</fpage>–<lpage>7500</lpage>.</citation>
</ref>
<ref id="bibr113-0004867412449303">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Merikangas</surname><given-names>KR</given-names></name>
<name><surname>Akiskal</surname><given-names>HS</given-names></name>
<name><surname>Angst</surname><given-names>J</given-names></name>
<etal/>
</person-group>. (<year>2007</year>) <article-title>Lifetime and 12-month prevalence of bipolar spectrum disorder in the National Comorbidity Survey replication</article-title>. <source>Archives of General Psychiatry</source> <volume>64</volume>: <fpage>543</fpage>–<lpage>552</lpage>.</citation>
</ref>
<ref id="bibr114-0004867412449303">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Modica-Napolitano</surname><given-names>J</given-names></name>
<name><surname>Renshaw</surname><given-names>PF</given-names></name>
</person-group> (<year>2004</year>) <article-title>Ethanolamine and phosphoethanolamine inhibit mitochondrial function in vitro: Implications for mitochondrial dysfunction hypothesis in depression and bipolar disorder</article-title>. <source>Biological Psychiatry</source> <volume>55</volume>: <fpage>273</fpage>–<lpage>277</lpage>.</citation>
</ref>
<ref id="bibr115-0004867412449303">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Moore</surname><given-names>CM</given-names></name>
<name><surname>Breeze</surname><given-names>JL</given-names></name>
<name><surname>Gruber</surname><given-names>SA</given-names></name>
<etal/>
</person-group>. (<year>2000</year>) <article-title>Choline, myo-inositol and mood in bipolar disorder: A proton magnetic resonance spectroscopic imaging study of the anterior cingulate cortex</article-title>. <source>Bipolar Disorders</source> <volume>2</volume>: <fpage>207</fpage>–<lpage>216</lpage>.</citation>
</ref>
<ref id="bibr116-0004867412449303">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Müller</surname><given-names>D</given-names></name>
<name><surname>de Luca</surname><given-names>V</given-names></name>
<name><surname>Sicard</surname><given-names>T</given-names></name>
<etal/>
</person-group>. (<year>2006</year>) <article-title>Brain-derived neurotrophic factor (BDNF) gene and rapid-cycling bipolar disorder: Family-based association study</article-title>. <source>British Journal of Psychiatry</source> <volume>189</volume>: <fpage>317</fpage>–<lpage>323</lpage>.</citation>
</ref>
<ref id="bibr117-0004867412449303">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Munakata</surname><given-names>K</given-names></name>
<name><surname>Fujii</surname><given-names>K</given-names></name>
<name><surname>Nanko</surname><given-names>S</given-names></name>
<etal/>
</person-group>. (<year>2007</year>) <article-title>Sequence and functional analyses of mtDNA in a maternally inherited family with bipolar disorder and depression</article-title>. <source>Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis</source> <volume>617</volume>: <fpage>119</fpage>–<lpage>124</lpage>.</citation>
</ref>
<ref id="bibr118-0004867412449303">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Munakata</surname><given-names>K</given-names></name>
<name><surname>Tanaka</surname><given-names>M</given-names></name>
<name><surname>Mori</surname><given-names>K</given-names></name>
<etal/>
</person-group>. (<year>2004</year>) <article-title>Mitochondrial DNA 3644T→C mutation associated with bipolar disorder</article-title>. <source>Genomics</source> <volume>84</volume>: <fpage>1041</fpage>–<lpage>1050</lpage>.</citation>
</ref>
<ref id="bibr119-0004867412449303">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Murphy</surname><given-names>A</given-names></name>
<name><surname>Bredesen</surname><given-names>D</given-names></name>
<name><surname>Cortopassi</surname><given-names>G</given-names></name>
<etal/>
</person-group>. (<year>1996</year>) <article-title>Bcl-2 potentiates the maximal calcium uptake capacity of neural cell mitochondria</article-title>. <source>Proceedings of the National Academy of Sciences of the United States of America</source> <volume>93</volume>: <fpage>9893</fpage>–<lpage>9898</lpage>.</citation>
</ref>
<ref id="bibr120-0004867412449303">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Nasca</surname><given-names>D</given-names></name>
<name><surname>Zurria</surname><given-names>G</given-names></name>
<name><surname>Aguglia</surname><given-names>E</given-names></name>
</person-group> (<year>1989</year>) <article-title>Action of acetyl-L-carnitine in association with mianserine on depressed old people</article-title>. <source>New Trends in Clinical Neuropharmacology</source> <volume>3</volume>: <fpage>225</fpage>–<lpage>230</lpage>.</citation>
</ref>
<ref id="bibr121-0004867412449303">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Naydenov</surname><given-names>AV</given-names></name>
<name><surname>MacDonald</surname><given-names>ML</given-names></name>
<name><surname>Ongur</surname><given-names>D</given-names></name>
<etal/>
</person-group>. (<year>2007</year>) <article-title>Differences in lymphocyte electron transport gene expression levels between subjects with bipolar disorder and normal controls in response to glucose deprivation stress</article-title>. <source>Archives in General Psychiatry</source> <volume>64</volume>: <fpage>555</fpage>–<lpage>564</lpage>.</citation>
</ref>
<ref id="bibr122-0004867412449303">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Negrişanu</surname><given-names>G</given-names></name>
<name><surname>Roşu</surname><given-names>M</given-names></name>
<name><surname>Bolte</surname><given-names>B</given-names></name>
<etal/>
</person-group>. (<year>1999</year>) <article-title>Effects of 3-month treatment with the antioxidant alpha-lipoic acid in diabetic peripheral neuropathy</article-title>. <source>Romanian Journal of Internal Medicine</source> <volume>37</volume>: <fpage>297</fpage>–<lpage>306</lpage>.</citation>
</ref>
<ref id="bibr123-0004867412449303">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ng</surname><given-names>F</given-names></name>
<name><surname>Berk</surname><given-names>M</given-names></name>
<name><surname>Dean</surname><given-names>O</given-names></name>
<etal/>
</person-group>. (<year>2008</year>) <article-title>Oxidative stress in psychiatric disorders: Evidence base and therapeutic implications</article-title>. <source>International Journal Neuropsychopharmacology</source> <volume>11</volume>: <fpage>851</fpage>–<lpage>876</lpage>.</citation>
</ref>
<ref id="bibr124-0004867412449303">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Nicholls</surname><given-names>D</given-names></name>
<name><surname>Ward</surname><given-names>M</given-names></name>
</person-group> (<year>2000</year>) <article-title>Mitochondrial membrane potential and neuronal glutamate excitotoxicity: Mortality and millivolts</article-title>. <source>Trends in Neuroscience</source> <volume>23</volume>: <fpage>166</fpage>–<lpage>174</lpage>.</citation>
</ref>
<ref id="bibr125-0004867412449303">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Nicoletti</surname><given-names>VG</given-names></name>
<name><surname>Marino</surname><given-names>VM</given-names></name>
<name><surname>Cuppari</surname><given-names>C</given-names></name>
<etal/>
</person-group>. (<year>2005</year>) <article-title>Effect of antioxidant diets and mitochondrial gene expression in rat brain during aging</article-title>. <source>Neurochemical Research</source> <volume>30</volume>: <fpage>737</fpage>–<lpage>752</lpage>.</citation>
</ref>
<ref id="bibr126-0004867412449303">
<citation citation-type="journal">
<collab>NINDS NET-PD Investigators</collab> (<year>2006</year>) <article-title>A randomized, double-blind, futility clinical trial of creatine and minocycline in early Parkinson disease</article-title>. <source>Neurology</source> <volume>66</volume>: <fpage>664</fpage>–<lpage>671</lpage>.</citation>
</ref>
<ref id="bibr127-0004867412449303">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Packer</surname><given-names>L</given-names></name>
<name><surname>Witt</surname><given-names>EH</given-names></name>
<name><surname>Tritschler</surname><given-names>HJ</given-names></name>
</person-group> (<year>1995</year>) <article-title>alpha-Lipoic acid as a biological antioxidant</article-title>. <source>Free Radical Biology &amp; Medicine</source> <volume>19</volume>: <fpage>227</fpage>–<lpage>250</lpage>.</citation>
</ref>
<ref id="bibr128-0004867412449303">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Papakostas</surname><given-names>GI</given-names></name>
<name><surname>Mischoulon</surname><given-names>D</given-names></name>
<name><surname>Shyu</surname><given-names>I</given-names></name>
<etal/>
</person-group>. (<year>2010</year>) <article-title><italic>S</italic>-adenosyl methionine (SAMe) augmentation of serotonin reuptake inhibitors for antidepressant nonresponders with major depressive disorder: A double-blind, randomized clinical trial</article-title>. <source>American Journal of Psychiatry</source> <volume>167</volume>: <fpage>942</fpage>–<lpage>948</lpage>.</citation>
</ref>
<ref id="bibr129-0004867412449303">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Pappolla</surname><given-names>M</given-names></name>
<name><surname>Bozner</surname><given-names>P</given-names></name>
<name><surname>Soto</surname><given-names>C</given-names></name>
<etal/>
</person-group>. (<year>1998</year>) <article-title>Inhibition of Alzheimer beta-fibrillogenesis by melatonin</article-title>. <source>Journal of Biological Chemistry</source> <volume>273</volume>: <fpage>7185</fpage>–<lpage>7188</lpage>.</citation>
</ref>
<ref id="bibr130-0004867412449303">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Passeri</surname><given-names>M</given-names></name>
<name><surname>Cucinotta</surname><given-names>D</given-names></name>
<name><surname>Bonati</surname><given-names>PA</given-names></name>
<etal/>
</person-group>. (<year>1990</year>) <article-title>Acetyl-L-carnitine in the treatment of mildly demented elderly patients</article-title>. <source>International Journal of Clinical Pharmacology Research</source> <volume>10</volume>: <fpage>75</fpage>–<lpage>79</lpage>.</citation>
</ref>
<ref id="bibr131-0004867412449303">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Patel</surname><given-names>T</given-names></name>
<name><surname>Clark</surname><given-names>J</given-names></name>
</person-group> (<year>1979</year>) <article-title>Synthesis of <italic>N</italic>-acetyl-L-aspartate by rat brain mitochondria and its involvement in mitochondrial/ cytosolic carbon transport</article-title>. <source>Biochemical Journal</source> <volume>184</volume>: <fpage>539</fpage>–<lpage>546</lpage>.</citation>
</ref>
<ref id="bibr132-0004867412449303">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Perlis</surname><given-names>RH</given-names></name>
<name><surname>Ostacher</surname><given-names>MJ</given-names></name>
<name><surname>Patel</surname><given-names>JK</given-names></name>
<etal/>
</person-group>. (<year>2006</year>) <article-title>Predictors of recurrence in bipolar disorder: Primary outcomes from the systematic treatment enhancement program for bipolar disorder (STEP-BD)</article-title>. <source>American Journal of Psychiatry</source> <volume>163</volume>: <fpage>217</fpage>–<lpage>224</lpage>.</citation>
</ref>
<ref id="bibr133-0004867412449303">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Peters</surname><given-names>A</given-names></name>
<name><surname>Schweiger</surname><given-names>U</given-names></name>
<name><surname>Pellerin</surname><given-names>L</given-names></name>
<etal/>
</person-group>. (<year>2004</year>) <article-title>The selfish brain: Competition for energy resources</article-title>. <source>Neuroscience and Biobehavioral Reviews</source> <volume>28</volume>: <fpage>143</fpage>–<lpage>180</lpage>.</citation>
</ref>
<ref id="bibr134-0004867412449303">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Pettegrew</surname><given-names>JW</given-names></name>
<name><surname>Klunk</surname><given-names>WE</given-names></name>
<name><surname>Panchalingam</surname><given-names>K</given-names></name>
<etal/>
</person-group>. (<year>1995</year>) <article-title>Clinical and neurochemical effects of acetyl-L-carnitine in Alzheimer’s disease</article-title>. <source>Neurobiology of Aging</source> <volume>16</volume>: <fpage>1</fpage>–<lpage>4</lpage>.</citation>
</ref>
<ref id="bibr135-0004867412449303">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Pettegrew</surname><given-names>JW</given-names></name>
<name><surname>Levine</surname><given-names>J</given-names></name>
<name><surname>Gershon</surname><given-names>S</given-names></name>
<etal/>
</person-group>. (<year>2002</year>) <article-title>31P-MRS study of acetyl-L-carnitine treatment in geriatric depression: Preliminary results</article-title>. <source>Bipolar Disorders</source> <volume>4</volume>: <fpage>61</fpage>–<lpage>66</lpage>.</citation>
</ref>
<ref id="bibr136-0004867412449303">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Purdon</surname><given-names>AD</given-names></name>
<name><surname>Rapoport</surname><given-names>SI</given-names></name>
</person-group> (<year>1998</year>) <article-title>Energy requirements for two aspects of phospholipid metabolism in mammalian brain</article-title>. <source>Biochemical Journal</source> <volume>335</volume>: <fpage>313</fpage>–<lpage>318</lpage>.</citation>
</ref>
<ref id="bibr137-0004867412449303">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Quiroz</surname><given-names>JA</given-names></name>
<name><surname>Gray</surname><given-names>NA</given-names></name>
<name><surname>Kato</surname><given-names>T</given-names></name>
<etal/>
</person-group>. (<year>2008</year>) <article-title>Mitochondrially mediated plasticity in the pathophysiology and treatment of bipolar disorder</article-title>. <source>Neuropsychopharmacology</source> <volume>33</volume>: <fpage>2551</fpage>–<lpage>2565</lpage>.</citation>
</ref>
<ref id="bibr138-0004867412449303">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Rebouche</surname><given-names>CJ</given-names></name>
</person-group> (<year>2004</year>) <article-title>Kinetics, pharmacokinetics, and regulation of L-carnitine and acetyl-L-carnitine metabolism</article-title>. <source>Annals of the New York Academy of Sciences</source> <volume>1033</volume>: <fpage>30</fpage>–<lpage>41</lpage>.</citation>
</ref>
<ref id="bibr139-0004867412449303">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Reiter</surname><given-names>RJ</given-names></name>
<name><surname>Cabrera</surname><given-names>J</given-names></name>
<name><surname>Sainz</surname><given-names>RM</given-names></name>
<etal/>
</person-group>. (<year>1999</year>) <article-title>Melatonin as a pharmacological agent against neuronal loss in experimental models of Huntington’s disease, Alzheimer’s disease and parkinsonism</article-title>. <source>Annals of the New York Academy of Sciences</source> <volume>890</volume>: <fpage>471</fpage>–<lpage>485</lpage>.</citation>
</ref>
<ref id="bibr140-0004867412449303">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Reiter</surname><given-names>RJ</given-names></name>
<name><surname>Tan</surname><given-names>DX</given-names></name>
<name><surname>Allegra</surname><given-names>M</given-names></name>
</person-group> (<year>2002a</year>) <article-title>Melatonin: Reducing molecular pathology and dysfunction due to free radicals and associated reactants</article-title>. <source>Neuro Endocrinology Letters</source> <volume>23</volume> <supplement>Suppl 1</supplement>: <fpage>3</fpage>–<lpage>8</lpage>.</citation>
</ref>
<ref id="bibr141-0004867412449303">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Reiter</surname><given-names>RJ</given-names></name>
<name><surname>Tan</surname><given-names>DX</given-names></name>
<name><surname>Burkhardt</surname><given-names>S</given-names></name>
</person-group> (<year>2002b</year>) <article-title>Reactive oxygen and nitrogen species and cellular and organismal decline: Amelioration with melatonin</article-title>. <source>Mechanisms of Ageing and Development</source> <volume>123</volume>: <fpage>1007</fpage>–<lpage>1019</lpage>.</citation>
</ref>
<ref id="bibr142-0004867412449303">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Reiter</surname><given-names>RJ</given-names></name>
<name><surname>Tan</surname><given-names>DX</given-names></name>
<name><surname>Manchester</surname><given-names>LC</given-names></name>
<etal/>
</person-group>. (<year>2003</year>) <article-title>Melatonin: Detoxification of oxygen and nitrogen-based toxic reactants</article-title>. <source>Advances in Experimental Medicine and Biology</source> <volume>527</volume>: <fpage>539</fpage>–<lpage>548</lpage>.</citation>
</ref>
<ref id="bibr143-0004867412449303">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Reljanovic</surname><given-names>M</given-names></name>
<name><surname>Reichel</surname><given-names>G</given-names></name>
<name><surname>Rett</surname><given-names>K</given-names></name>
<etal/>
</person-group>. (<year>1999</year>) <article-title>Treatment of diabetic polyneuropathy with the antioxidant thioctic acid (alpha-lipoic acid): A two year multicenter randomized double-blind placebo-controlled trial (ALADIN II). Alpha Lipoic Acid in Diabetic Neuropathy</article-title>. <source>Free Radical Research</source> <volume>31</volume>: <fpage>171</fpage>–<lpage>179</lpage>.</citation>
</ref>
<ref id="bibr144-0004867412449303">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Richer</surname><given-names>C</given-names></name>
<name><surname>Park</surname><given-names>J-W</given-names></name>
<name><surname>Ames</surname><given-names>BN</given-names></name>
</person-group> (<year>1988</year>) <article-title>Normal oxidative damage to mitochondrial and nuclear DNA is extensive</article-title>. <source>Proceedings of the National Academy of Sciences of the United States of America</source> <volume>85</volume>: <fpage>6465</fpage>–<lpage>6467</lpage>.</citation>
</ref>
<ref id="bibr145-0004867412449303">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Rodriguez</surname><given-names>C</given-names></name>
<name><surname>Mayo</surname><given-names>JC</given-names></name>
<name><surname>Sainz</surname><given-names>RM</given-names></name>
<etal/>
</person-group>. (<year>2004</year>) <article-title>Regulation of antioxidant enzymes: A significant role for melatonin</article-title>. <source>Journal of Pineal Research</source> <volume>36</volume>: <fpage>1</fpage>–<lpage>9</lpage>.</citation>
</ref>
<ref id="bibr146-0004867412449303">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Rodriguez</surname><given-names>MC</given-names></name>
<name><surname>MacDonald</surname><given-names>JR</given-names></name>
<name><surname>Mahoney</surname><given-names>DJ</given-names></name>
<etal/>
</person-group>. (<year>2007</year>) <article-title>Beneficial effects of creatine, CoQ10, and lipoic acid in mitochondrial disorders</article-title>. <source>Muscle &amp; Nerve</source> <volume>35</volume>: <fpage>235</fpage>–<lpage>242</lpage>.</citation>
</ref>
<ref id="bibr147-0004867412449303">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Roitman</surname><given-names>S</given-names></name>
<name><surname>Green</surname><given-names>T</given-names></name>
<name><surname>Osher</surname><given-names>Y</given-names></name>
<etal/>
</person-group>. (<year>2007</year>) <article-title>Creatine monohydrate in resistant depression: A preliminary study</article-title>. <source>Bipolar Disorders</source> <volume>9</volume>: <fpage>754</fpage>–<lpage>758</lpage>.</citation>
</ref>
<ref id="bibr148-0004867412449303">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Rosenfeld</surname><given-names>J</given-names></name>
<name><surname>King</surname><given-names>RM</given-names></name>
<name><surname>Jackson</surname><given-names>CE</given-names></name>
<etal/>
</person-group>. (<year>2008</year>) <article-title>Creatine monohydrate in ALS: Effects on strength, fatigue, respiratory status and ALSFRS</article-title>. <source>Amyotrophic Lateral Sclerosis</source> <volume>9</volume>: <fpage>266</fpage>–<lpage>272</lpage>.</citation>
</ref>
<ref id="bibr149-0004867412449303">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Rosenfeldt</surname><given-names>FL</given-names></name>
<name><surname>Haas</surname><given-names>SJ</given-names></name>
<name><surname>Krum</surname><given-names>H</given-names></name>
<etal/>
</person-group>. (<year>2007</year>) <article-title>Coenzyme Q(10) in the treatment of hypertension: A meta-analysis of the clinical trials</article-title>. <source>Journal of Human Hypertension</source> <volume>21</volume>: <fpage>297</fpage>–<lpage>306</lpage>.</citation>
</ref>
<ref id="bibr150-0004867412449303">
<citation citation-type="book">
<person-group person-group-type="author">
<name><surname>Rothman</surname><given-names>DL</given-names></name>
</person-group> (<year>1994</year>) <article-title>1H NMR studies of human brain metabolism and physiology</article-title>. In: <person-group person-group-type="editor">
<name><surname>Gilles</surname><given-names>RJ</given-names></name>
</person-group> (ed) <source>NMR in Physiology and Biomedicine</source>. <publisher-loc>San Diego, CA</publisher-loc>: <publisher-name>Academic Press</publisher-name>, pp.<fpage>353</fpage>–<lpage>372</lpage>.</citation>
</ref>
<ref id="bibr151-0004867412449303">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Rudich</surname><given-names>A</given-names></name>
<name><surname>Tirosh</surname><given-names>A</given-names></name>
<name><surname>Potashnik</surname><given-names>R</given-names></name>
<etal/>
</person-group>. (<year>1999</year>) <article-title>Lipoic acid protects against oxidative stress induced impairment in insulin stimulation of protein kinase B and glucose transport in 3T3-L1 adipocytes</article-title>. <source>Diabetologia</source> <volume>42</volume>: <fpage>949</fpage>–<lpage>957</lpage>.</citation>
</ref>
<ref id="bibr152-0004867412449303">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ruhnau</surname><given-names>KJ</given-names></name>
<name><surname>Meissner</surname><given-names>HP</given-names></name>
<name><surname>Finn</surname><given-names>JR</given-names></name>
<etal/>
</person-group>. (<year>1999</year>) <article-title>Effects of 3-week oral treatment with the antioxidant thioctic acid (alpha-lipoic acid) in symptomatic diabetic polyneuropathy</article-title>. <source>Diabetic Medicine</source> <volume>16</volume>: <fpage>1040</fpage>–<lpage>1043</lpage>.</citation>
</ref>
<ref id="bibr153-0004867412449303">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Salvioli</surname><given-names>G</given-names></name>
<name><surname>Neri</surname><given-names>M</given-names></name>
</person-group> (<year>1994</year>) <article-title>L-Acetylcarnitine treatment of mental decline in the elderly</article-title>. <source>Drugs Under Experimental and Clinical Research</source> <volume>20</volume>: <fpage>169</fpage>–<lpage>176</lpage>.</citation>
</ref>
<ref id="bibr154-0004867412449303">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Sandor</surname><given-names>PS</given-names></name>
<name><surname>Di Clemente</surname><given-names>L</given-names></name>
<name><surname>Coppola</surname><given-names>G</given-names></name>
<etal/>
</person-group>. (<year>2005</year>) <article-title>Efficacy of coenzyme Q10 in migraine prophylaxis: A randomized controlled trial</article-title>. <source>Neurology</source> <volume>64</volume>: <fpage>713</fpage>–<lpage>715</lpage>.</citation>
</ref>
<ref id="bibr155-0004867412449303">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Sano</surname><given-names>M</given-names></name>
<name><surname>Bell</surname><given-names>K</given-names></name>
<name><surname>Cote</surname><given-names>L</given-names></name>
<etal/>
</person-group>. (<year>1992</year>) <article-title>Double-blind parallel design pilot study of acetyl levocarnitine in patients with Alzheimer’s disease</article-title>. <source>Archives of Neurology</source> <volume>49</volume>: <fpage>1137</fpage>–<lpage>1141</lpage>.</citation>
</ref>
<ref id="bibr156-0004867412449303">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Sarris</surname><given-names>J</given-names></name>
<name><surname>Mischoulon</surname><given-names>D</given-names></name>
<name><surname>Schweitzer</surname><given-names>I</given-names></name>
</person-group> (<year>2011</year>) <article-title>Adjunctive nutraceuticals with standard pharmacotherapies in bipolar disorder: A systematic review of clinical trials</article-title>. <source>Bipolar Disorders</source> <volume>13</volume>: <fpage>454</fpage>–<lpage>465</lpage>.</citation>
</ref>
<ref id="bibr157-0004867412449303">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Sauter</surname><given-names>A</given-names></name>
<name><surname>Rudin</surname><given-names>M</given-names></name>
</person-group> (<year>1993</year>) <article-title>Determination of creatine kinase kinetic parameters in rat brain by NMR magnetization transfer. Correlation with brain function</article-title>. <source>Journal of Biological Chemistry</source> <volume>268</volume>: <fpage>13,166</fpage>–<lpage>13,171</lpage>.</citation>
</ref>
<ref id="bibr158-0004867412449303">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Saxena</surname><given-names>R</given-names></name>
<name><surname>de Bakker</surname><given-names>PIW</given-names></name>
<name><surname>Singer</surname><given-names>K</given-names></name>
<etal/>
</person-group>. (<year>2006</year>) <article-title>Comprehensive association testing of common mitochondrial DNA variation in metabolic disease</article-title>. <source>American Journal of Human Genetics</source> <volume>79</volume>: <fpage>54</fpage>–<lpage>61</lpage>.</citation>
</ref>
<ref id="bibr159-0004867412449303">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Shao</surname><given-names>L</given-names></name>
<name><surname>Cui</surname><given-names>J</given-names></name>
<name><surname>Young</surname><given-names>LT</given-names></name>
<etal/>
</person-group>. (<year>2008a</year>) <article-title>The effect of mood stabilizer lithium on expression and activity of glutathione <italic>s</italic>-transferase isoenzymes</article-title>. <source>Neuroscience</source> <volume>151</volume>: <fpage>518</fpage>–<lpage>524</lpage>.</citation>
</ref>
<ref id="bibr160-0004867412449303">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Shao</surname><given-names>L</given-names></name>
<name><surname>Martin</surname><given-names>MV</given-names></name>
<name><surname>Watson</surname><given-names>SJ</given-names></name>
<etal/>
</person-group>. (<year>2008b</year>) <article-title>Mitochondrial involvement in psychiatric disorders</article-title>. <source>Annals of Medicine</source> <volume>40</volume>: <fpage>281</fpage>–<lpage>295</lpage>.</citation>
</ref>
<ref id="bibr161-0004867412449303">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Shea</surname><given-names>TB</given-names></name>
</person-group> (<year>2007</year>) <article-title>Effects of dietary supplementation with <italic>N</italic>-acetyl cysteine, acetyl-L-carnitine and <italic>S</italic>-adenosyl methionine on cognitive performance and aggression in normal mice and mice expressing human ApoE4</article-title>. <source>Neuromolecular Medicine</source> <volume>9</volume>: <fpage>264</fpage>–<lpage>269</lpage>.</citation>
</ref>
<ref id="bibr162-0004867412449303">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Shults</surname><given-names>CW</given-names></name>
<name><surname>Haas</surname><given-names>R</given-names></name>
</person-group> (<year>2005</year>) <article-title>Clinical trials of coenzyme Q10 in neurological disorders</article-title>. <source>Biofactors</source> <volume>25</volume>: <fpage>117</fpage>–<lpage>126</lpage>.</citation>
</ref>
<ref id="bibr163-0004867412449303">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Shults</surname><given-names>CW</given-names></name>
<name><surname>Beal</surname><given-names>MF</given-names></name>
<name><surname>Song</surname><given-names>D</given-names></name>
<etal/>
</person-group>. (<year>2004</year>) <article-title>Pilot trial of high dosages of coenzyme Q(10) in patients with Parkinson’s disease</article-title>. <source>Experimental Neurology</source> <volume>188</volume>: <fpage>491</fpage>–<lpage>494</lpage>.</citation>
</ref>
<ref id="bibr164-0004867412449303">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Shults</surname><given-names>CW</given-names></name>
<name><surname>Haas</surname><given-names>RH</given-names></name>
<name><surname>Passov</surname><given-names>D</given-names></name>
<etal/>
</person-group>. (<year>1997</year>) <article-title>Coenzyme Q10 levels correlate with the activities of complexes I and II/III in mitochondria from parkinsonian and nonparkinsonian subjects</article-title>. <source>Annals of Neurology</source> <volume>42</volume>: <fpage>261</fpage>–<lpage>264</lpage>.</citation>
</ref>
<ref id="bibr165-0004867412449303">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Shults</surname><given-names>CW</given-names></name>
<name><surname>Oakes</surname><given-names>D</given-names></name>
<name><surname>Kieburtz</surname><given-names>K</given-names></name>
<etal/>
</person-group>. (<year>2002</year>) <article-title>Effects of coenzyme Q10 in early Parkinson disease: Evidence of slowing of the functional decline</article-title>. <source>Archives of Neurology</source> <volume>59</volume>: <fpage>1541</fpage>–<lpage>1550</lpage>.</citation>
</ref>
<ref id="bibr166-0004867412449303">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Silva</surname><given-names>M</given-names></name>
<name><surname>Aires</surname><given-names>C</given-names></name>
<name><surname>Luis</surname><given-names>P</given-names></name>
<etal/>
</person-group>. (<year>2008</year>) <article-title>Valproic acid metabolism and its effects on mitochondrial fatty acid oxidation: A review</article-title>. <source>Journal of Inherited Metabolic Disease</source> <volume>31</volume>: <fpage>205</fpage>–<lpage>216</lpage>.</citation>
</ref>
<ref id="bibr167-0004867412449303">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Sima</surname><given-names>AA</given-names></name>
<name><surname>Calvani</surname><given-names>M</given-names></name>
<name><surname>Mehra</surname><given-names>M</given-names></name>
<etal/>
</person-group>. (<year>2005</year>) <article-title>Acetyl-L-carnitine improves pain, nerve regeneration, and vibratory perception in patients with chronic diabetic neuropathy: An analysis of two randomized placebo-controlled trials</article-title>. <source>Diabetes Care</source> <volume>28</volume>: <fpage>89</fpage>–<lpage>94</lpage>.</citation>
</ref>
<ref id="bibr168-0004867412449303">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Sklar</surname><given-names>P</given-names></name>
<name><surname>Smoller</surname><given-names>JW</given-names></name>
<name><surname>Fan</surname><given-names>J</given-names></name>
<etal/>
</person-group>. (<year>2008</year>) <article-title>Whole-genome association study of bipolar disorder</article-title>. <source>Molecular Psychiatry</source> <volume>13</volume>: <fpage>558</fpage>–<lpage>569</lpage>.</citation>
</ref>
<ref id="bibr169-0004867412449303">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Soczynska</surname><given-names>JK</given-names></name>
<name><surname>Kennedy</surname><given-names>SH</given-names></name>
<name><surname>Chow</surname><given-names>CS</given-names></name>
<etal/>
</person-group>. (<year>2008</year>) <article-title>Acetyl-L-carnitine and alpha-lipoic acid: Possible neurotherapeutic agents for mood disorders?</article-title> <source>Expert Opinion on Investigational Drugs</source> <volume>17</volume>: <fpage>827</fpage>–<lpage>843</lpage>.</citation>
</ref>
<ref id="bibr170-0004867412449303">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Sohmiya</surname><given-names>M</given-names></name>
<name><surname>Tanaka</surname><given-names>M</given-names></name>
<name><surname>Tak</surname><given-names>NW</given-names></name>
<etal/>
</person-group>. (<year>2004</year>) <article-title>Redox status of plasma coenzyme Q10 indicates elevated systemic oxidative stress in Parkinson’s disease</article-title>. <source>Journal of the Neurological Sciences</source> <volume>223</volume>: <fpage>161</fpage>–<lpage>166</lpage>.</citation>
</ref>
<ref id="bibr171-0004867412449303">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Sorbi</surname><given-names>S</given-names></name>
<name><surname>Forleo</surname><given-names>P</given-names></name>
<name><surname>Fani</surname><given-names>C</given-names></name>
<etal/>
</person-group>. (<year>2000</year>) <article-title>Double-blind, crossover, placebo-controlled clinical trial with L-acetylcarnitine in patients with degenerative cerebellar ataxia</article-title>. <source>Clinical Neuropharmacology</source> <volume>23</volume>: <fpage>114</fpage>–<lpage>118</lpage>.</citation>
</ref>
<ref id="bibr172-0004867412449303">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Spagnoli</surname><given-names>A</given-names></name>
<name><surname>Lucca</surname><given-names>U</given-names></name>
<name><surname>Menasce</surname><given-names>G</given-names></name>
<etal/>
</person-group>. (<year>1991</year>) <article-title>Long-term acetyl-L-carnitine treatment in Alzheimer’s disease</article-title>. <source>Neurology</source> <volume>41</volume>: <fpage>1726</fpage>–<lpage>1732</lpage>.</citation>
</ref>
<ref id="bibr173-0004867412449303">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Storch</surname><given-names>A</given-names></name>
<name><surname>Jost</surname><given-names>WH</given-names></name>
<name><surname>Vieregge</surname><given-names>P</given-names></name>
<etal/>
</person-group>. (<year>2007</year>) <article-title>Randomized, double-blind, placebo-controlled trial on symptomatic effects of coenzyme Q10 in Parkinson disease</article-title>. <source>Archives of Neurology</source> <volume>64</volume>: <fpage>938</fpage>–<lpage>944</lpage>.</citation>
</ref>
<ref id="bibr174-0004867412449303">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Stork</surname><given-names>C</given-names></name>
<name><surname>Renshaw</surname><given-names>PF</given-names></name>
</person-group> (<year>2005</year>) <article-title>Mitochondrial dysfunction in bipolar disorder: Evidence from magnetic resonance spectroscopy research</article-title>. <source>Molecular Psychiatry</source> <volume>10</volume>: <fpage>900</fpage>–<lpage>919</lpage>.</citation>
</ref>
<ref id="bibr175-0004867412449303">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Strijks</surname><given-names>E</given-names></name>
<name><surname>Kremer</surname><given-names>HPH</given-names></name>
<name><surname>Horstink</surname><given-names>M</given-names></name>
</person-group> (<year>1997</year>) <article-title>Q(10) therapy in patients with idiopathic Parkinson’s disease</article-title>. <source>Molecular Aspects of Medicine</source> <year>1997</year>; <volume>18</volume> <supplement>Suppl</supplement>: <fpage>S237</fpage>–<lpage>S240</lpage>.</citation>
</ref>
<ref id="bibr176-0004867412449303">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Sullivan</surname><given-names>PG</given-names></name>
<name><surname>Geiger</surname><given-names>JD</given-names></name>
<name><surname>Mattson</surname><given-names>MP</given-names></name>
<etal/>
</person-group>. (<year>2000</year>) <article-title>Dietary supplement creatine protects against traumatic brain injury</article-title>. <source>Annals of Neurology</source> <volume>48</volume>: <fpage>723</fpage>–<lpage>729</lpage>.</citation>
</ref>
<ref id="bibr177-0004867412449303">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Sun</surname><given-names>X</given-names></name>
<name><surname>Wang</surname><given-names>J-F</given-names></name>
<name><surname>Tseng</surname><given-names>M</given-names></name>
<etal/>
</person-group>. (<year>2006</year>) <article-title>Downregulation in components of the mitochondrial electron transport chain in the postmortem frontal cortex of subjects with bipolar disorder</article-title>. <source>Journal of Psychiatry &amp; Neuroscience</source> <volume>31</volume>: <fpage>189</fpage>–<lpage>196</lpage>.</citation>
</ref>
<ref id="bibr178-0004867412449303">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Tabrizi</surname><given-names>SJ</given-names></name>
<name><surname>Blamire</surname><given-names>AM</given-names></name>
<name><surname>Manners</surname><given-names>DN</given-names></name>
<etal/>
</person-group>. (<year>2005</year>) <article-title>High-dose creatine therapy for Huntington disease: A 2-year clinical and MRS study</article-title>. <source>Neurology</source> <volume>64</volume>: <fpage>1655</fpage>–<lpage>1656</lpage>.</citation>
</ref>
<ref id="bibr179-0004867412449303">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Tan</surname><given-names>DX</given-names></name>
<name><surname>Manchester</surname><given-names>LC</given-names></name>
<name><surname>Reiter</surname><given-names>RJ</given-names></name>
<etal/>
</person-group>. (<year>1998</year>) <article-title>A novel melatonin metabolite, cyclic 3-hydroxymelatonin: A biomarker of in vivo hydroxyl radical generation</article-title>. <source>Biochemical and Biophysical Research Communications</source> <volume>253</volume>: <fpage>614</fpage>–<lpage>620</lpage>.</citation>
</ref>
<ref id="bibr180-0004867412449303">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Tankova</surname><given-names>T</given-names></name>
<name><surname>Koev</surname><given-names>D</given-names></name>
<name><surname>Dakovska</surname><given-names>L</given-names></name>
</person-group> (<year>2004</year>) <article-title>Alpha-lipoic acid in the treatment of autonomic diabetic neuropathy (controlled, randomized, open-label study)</article-title>. <source>Romanian Journal of Internal Medicine</source> <volume>42</volume>: <fpage>457</fpage>–<lpage>464</lpage>.</citation>
</ref>
<ref id="bibr181-0004867412449303">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Tarnopolsky</surname><given-names>MA</given-names></name>
</person-group> (<year>2008</year>) <article-title>The mitochondrial cocktail: Rationale for combined nutraceutical therapy in mitochondrial cytopathies</article-title>. <source>Advanced Drug Delivery Reviews</source> <volume>60</volume>: <fpage>1561</fpage>–<lpage>1567</lpage>.</citation>
</ref>
<ref id="bibr182-0004867412449303">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Tarnopolsky</surname><given-names>MA</given-names></name>
<name><surname>Beal</surname><given-names>MF</given-names></name>
</person-group> (<year>2001</year>) <article-title>Potential for creatine and other therapies targeting cellular energy dysfunction in neurological disorders</article-title>. <source>Annals of Neurology</source> <volume>49</volume>: <fpage>561</fpage>–<lpage>574</lpage>.</citation>
</ref>
<ref id="bibr183-0004867412449303">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Tarnopolsky</surname><given-names>MA</given-names></name>
<name><surname>Mahoney</surname><given-names>DJ</given-names></name>
<name><surname>Vajsar</surname><given-names>J</given-names></name>
<etal/>
</person-group>. (<year>2004</year>) <article-title>Creatine monohydrate enhances strength and body composition in Duchenne muscular dystrophy</article-title>. <source>Neurology</source> <volume>62</volume>: <fpage>1771</fpage>–<lpage>1777</lpage>.</citation>
</ref>
<ref id="bibr184-0004867412449303">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Tarnopolsky</surname><given-names>MA</given-names></name>
<name><surname>Roy</surname><given-names>BD</given-names></name>
<name><surname>MacDonald</surname><given-names>JR</given-names></name>
</person-group> (<year>1997</year>) <article-title>A randomized, controlled trial of creatine monohydrate in patients with mitochondrial cytopathies</article-title>. <source>Muscle &amp; Nerve</source> <volume>20</volume>: <fpage>1502</fpage>–<lpage>1509</lpage>.</citation>
</ref>
<ref id="bibr185-0004867412449303">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Taylor</surname><given-names>RW</given-names></name>
<name><surname>Turnbull</surname><given-names>DM</given-names></name>
</person-group> (<year>2005</year>) <article-title>Mitochondrial DNA mutations in human disease</article-title>. <source>Nature Reviews. Genetics</source> <volume>6</volume>: <fpage>389</fpage>–<lpage>402</lpage>.</citation>
</ref>
<ref id="bibr186-0004867412449303">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Tempesta</surname><given-names>E</given-names></name>
<name><surname>Casella</surname><given-names>L</given-names></name>
<name><surname>Pirrongelli</surname><given-names>C</given-names></name>
<etal/>
</person-group>. (<year>1987</year>) <article-title>L-Acetylcarnitine in depressed elderly subjects. A cross-over study vs placebo</article-title>. <source>Drugs Under Experimental and Clinical Research</source> <volume>13</volume>: <fpage>417</fpage>–<lpage>423</lpage>.</citation>
</ref>
<ref id="bibr187-0004867412449303">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Terjung</surname><given-names>RL</given-names></name>
<name><surname>Clarkson</surname><given-names>P</given-names></name>
<name><surname>Eichner</surname><given-names>ER</given-names></name>
<etal/>
</person-group>. (<year>2000</year>) <article-title>American College of Sports Medicine roundtable. The physiological and health effects of oral creatine supplementation</article-title>. <source>Medicine and Science in Sports and Exercise</source> <volume>32</volume>: <fpage>706</fpage>–<lpage>717</lpage>.</citation>
</ref>
<ref id="bibr188-0004867412449303">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Torrioli</surname><given-names>MG</given-names></name>
<name><surname>Vernacotola</surname><given-names>S</given-names></name>
<name><surname>Mariotti</surname><given-names>P</given-names></name>
<etal/>
</person-group>. (<year>1999</year>) <article-title>Double-blind, placebo-controlled study of L-acetylcarnitine for the treatment of hyperactive behavior in fragile X syndrome</article-title>. <source>American Journal of Medical Genetics</source> <volume>87</volume>: <fpage>366</fpage>–<lpage>368</lpage>.</citation>
</ref>
<ref id="bibr189-0004867412449303">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Torrioli</surname><given-names>MG</given-names></name>
<name><surname>Vernacotola</surname><given-names>S</given-names></name>
<name><surname>Peruzzi</surname><given-names>L</given-names></name>
<etal/>
</person-group>. (<year>2008</year>) <article-title>A double-blind, parallel, multicenter comparison of L-acetylcarnitine with placebo on the attention deficit hyperactivity disorder in fragile X syndrome boys</article-title>. <source>American Journal of Medical Genetics. Part A</source> <volume>146A</volume>: <fpage>803</fpage>–<lpage>812</lpage>.</citation>
</ref>
<ref id="bibr190-0004867412449303">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Verbessem</surname><given-names>P</given-names></name>
<name><surname>Lemiere</surname><given-names>J</given-names></name>
<name><surname>Eijnde</surname><given-names>BO</given-names></name>
<etal/>
</person-group>. (<year>2003</year>) <article-title>Creatine supplementation in Huntington’s disease: A placebo-controlled pilot trial</article-title>. <source>Neurology</source> <volume>61</volume>: <fpage>925</fpage>–<lpage>930</lpage>.</citation>
</ref>
<ref id="bibr191-0004867412449303">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Villardita</surname><given-names>C</given-names></name>
<name><surname>Smirni</surname><given-names>P</given-names></name>
<name><surname>Vecchio</surname><given-names>I</given-names></name>
</person-group> (<year>1983</year>) <article-title>Acetyl-L-carnitine in depressed geriatric patients</article-title>. <source>European Review for Medical and Pharmacological Sciences</source> <volume>6</volume>: <fpage>1</fpage>–<lpage>12</lpage>.</citation>
</ref>
<ref id="bibr192-0004867412449303">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Vincent</surname><given-names>HK</given-names></name>
<name><surname>Bourguignon</surname><given-names>CM</given-names></name>
<name><surname>Vincent</surname><given-names>KR</given-names></name>
<etal/>
</person-group>. (<year>2007</year>) <article-title>Effects of alpha-lipoic acid supplementation in peripheral arterial disease: A pilot study</article-title>. <source>Journal of Alternative and Complementary Medicine</source> <volume>13</volume>: <fpage>577</fpage>–<lpage>584</lpage>.</citation>
</ref>
<ref id="bibr193-0004867412449303">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Virmani</surname><given-names>A</given-names></name>
<name><surname>Gaetani</surname><given-names>F</given-names></name>
<name><surname>Biniend</surname><given-names>Z</given-names></name>
</person-group> (<year>2005</year>) <article-title>Effects of metabolic modifiers such as carnitines, coenzyme Q10, and PUFAs against different forms of neurotoxic insults: Metabolic inhibitors, MPTP, and methamphetamine</article-title>. <source>Annals of the New York Academy of Sciences</source> <volume>1053</volume>: <fpage>183</fpage>–<lpage>191</lpage>.</citation>
</ref>
<ref id="bibr194-0004867412449303">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Walter</surname><given-names>MC</given-names></name>
<name><surname>Lochmuller</surname><given-names>H</given-names></name>
<name><surname>Reilich</surname><given-names>P</given-names></name>
<etal/>
</person-group>. (<year>2000</year>) <article-title>Creatine monohydrate in muscular dystrophies: A double-blind, placebo-controlled clinical study</article-title>. <source>Neurology</source> <volume>54</volume>: <fpage>1848</fpage>–<lpage>1850</lpage>.</citation>
</ref>
<ref id="bibr195-0004867412449303">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Wang</surname><given-names>J-F</given-names></name>
</person-group>. (<year>2007</year>) <article-title>Defects of mitochondrial electron transport chain in bipolar disorder: Implications for mood-stabilizing treatment</article-title>. <source>Canadian Journal of Psychiatry-Revue Canadienne De Psychiatrie</source> <volume>52</volume>: <fpage>753</fpage>–<lpage>762</lpage>.</citation>
</ref>
<ref id="bibr196-0004867412449303">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Weeber</surname><given-names>E</given-names></name>
<name><surname>Levy</surname><given-names>M</given-names></name>
<name><surname>Sampson</surname><given-names>M</given-names></name>
<etal/>
</person-group>. (<year>2002</year>) <article-title>The role of mitochondrial porins and the permeability transition pore in learning and synaptic plasticity</article-title>. <source>Journal of Biological Chemistry</source> <volume>277</volume>: <fpage>18,891</fpage>–<lpage>18,897</lpage>.</citation>
</ref>
<ref id="bibr197-0004867412449303">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Weissman</surname><given-names>MM</given-names></name>
<name><surname>Bland</surname><given-names>RC</given-names></name>
<name><surname>Canino</surname><given-names>GJ</given-names></name>
<etal/>
</person-group>. (<year>1996</year>) <article-title>Cross-national epidemiology of major depression and bipolar disorder</article-title>. <source>Journal of the American Medical Association</source> <volume>276</volume>: <fpage>293</fpage>–<lpage>299</lpage>.</citation>
</ref>
<ref id="bibr198-0004867412449303">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Winiarska</surname><given-names>K</given-names></name>
<name><surname>Fraczyk</surname><given-names>T</given-names></name>
<name><surname>Malinska</surname><given-names>D</given-names></name>
<etal/>
</person-group>. (<year>2006</year>) <article-title>Melatonin attenuates diabetes-induced oxidative stress in rabbits</article-title>. <source>Journal of Pineal Research</source> <volume>40</volume>: <fpage>168</fpage>–<lpage>176</lpage>.</citation>
</ref>
<ref id="bibr199-0004867412449303">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Yadav</surname><given-names>V</given-names></name>
<name><surname>Marracci</surname><given-names>G</given-names></name>
<name><surname>Lovera</surname><given-names>J</given-names></name>
<etal/>
</person-group>. (<year>2005</year>) <article-title>Lipoic acid in multiple sclerosis: A pilot study</article-title>. <source>Multiple Sclerosis</source> <volume>11</volume>: <fpage>159</fpage>–<lpage>165</lpage>.</citation>
</ref>
<ref id="bibr200-0004867412449303">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Yang</surname><given-names>F</given-names></name>
<name><surname>He</surname><given-names>X</given-names></name>
<name><surname>Russell</surname><given-names>J</given-names></name>
<etal/>
</person-group>. (<year>2003</year>) <article-title>Ca<sup>2+</sup> influx-independent synaptic potentiation mediated by mitochondrial Na(<sup>+</sup>)-Ca<sup>2+</sup> exchanger and protein kinase C</article-title>. <source>Journal of Cell Biology</source> <volume>163</volume>: <fpage>511</fpage>–<lpage>523</lpage>.</citation>
</ref>
<ref id="bibr201-0004867412449303">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Yildiz</surname><given-names>A</given-names></name>
<name><surname>Sachs</surname><given-names>GS</given-names></name>
<name><surname>Dorer</surname><given-names>DJ</given-names></name>
<etal/>
</person-group>. (<year>2001</year>) <article-title>P-31 Nuclear magnetic resonance spectroscopy findings in bipolar illness: A meta-analysis</article-title>. <source>Psychiatry Research Neuroimaging</source> <volume>106</volume>: <fpage>181</fpage>–<lpage>191</lpage>.</citation>
</ref>
<ref id="bibr202-0004867412449303">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Youle</surname><given-names>M</given-names></name>
<name><surname>Osio</surname><given-names>M</given-names></name>
</person-group> (<year>2007</year>) <article-title>A double-blind, parallel-group, placebo-controlled, multicentre study of acetyl L-carnitine in the symptomatic treatment of antiretroviral toxic neuropathy in patients with HIV-1 infection</article-title>. <source>HIV Medicine</source> <volume>8</volume>: <fpage>241</fpage>–<lpage>250</lpage>.</citation>
</ref>
<ref id="bibr203-0004867412449303">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Zanardi</surname><given-names>R</given-names></name>
<name><surname>Smeraldi</surname><given-names>E</given-names></name>
</person-group> (<year>2006</year>) <article-title>A double-blind, randomised, controlled clinical trial of acetyl-L-carnitine vs. amisulpride in the treatment of dysthymia</article-title>. <source>European Neuropsychopharmacology</source> <volume>16</volume>: <fpage>281</fpage>–<lpage>287</lpage>.</citation>
</ref>
<ref id="bibr204-0004867412449303">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ziegler</surname><given-names>D</given-names></name>
<name><surname>Ametov</surname><given-names>A</given-names></name>
<name><surname>Barinov</surname><given-names>A</given-names></name>
<etal/>
</person-group>. (<year>2006</year>) <article-title>Oral treatment with alpha-lipoic acid improves symptomatic diabetic polyneuropathy: The SYDNEY 2 trial</article-title>. <source>Diabetes Care</source> <volume>29</volume>: <fpage>2365</fpage>–<lpage>2370</lpage>.</citation>
</ref>
<ref id="bibr205-0004867412449303">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ziegler</surname><given-names>D</given-names></name>
<name><surname>Hanefeld</surname><given-names>M</given-names></name>
<name><surname>Ruhnau</surname><given-names>KJ</given-names></name>
<etal/>
</person-group>. (<year>1995</year>) <article-title>Treatment of symptomatic diabetic peripheral neuropathy with the anti-oxidant alpha-lipoic acid. A 3-week multicentre randomized controlled trial (ALADIN Study)</article-title>. <source>Diabetologia</source> <volume>38</volume>: <fpage>1425</fpage>–<lpage>1433</lpage>.</citation>
</ref>
<ref id="bibr206-0004867412449303">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ziegler</surname><given-names>D</given-names></name>
<name><surname>Hanefeld</surname><given-names>M</given-names></name>
<name><surname>Ruhnau</surname><given-names>KJ</given-names></name>
<etal/>
</person-group>. (<year>1999</year>) <article-title>Treatment of symptomatic diabetic polyneuropathy with the antioxidant alpha-lipoic acid: A 7-month multicenter randomized controlled trial (ALADIN III Study). ALADIN III Study Group. Alpha-Lipoic Acid in Diabetic Neuropathy</article-title>. <source>Diabetes Care</source> <volume>22</volume>: <fpage>1296</fpage>–<lpage>1301</lpage>.</citation>
</ref>
<ref id="bibr207-0004867412449303">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ziegler</surname><given-names>D</given-names></name>
<name><surname>Schatz</surname><given-names>H</given-names></name>
<name><surname>Conrad</surname><given-names>F</given-names></name>
<etal/>
</person-group>. (<year>1997</year>) <article-title>Effects of treatment with the antioxidant alpha-lipoic acid on cardiac autonomic neuropathy in NIDDM patients. A 4-month randomized controlled multicenter trial (DEKAN Study). Deutsche Kardiale Autonome Neuropathie</article-title>. <source>Diabetes Care</source> <volume>20</volume>: <fpage>369</fpage>–<lpage>373</lpage>.</citation>
</ref>
</ref-list>
</back>
</article>